

# The mechanism(s) of action of antioxidants: From scavenging reactive oxygen/nitrogen species to redox signaling and the generation of bioactive secondary metabolites

Attila Hunyadi<sup>1,2</sup> 

<sup>1</sup>Institute of Pharmacognosy, Interdisciplinary Excellence Centre, University of Szeged, Eötvös str. 6, H-6720, Szeged, Hungary

<sup>2</sup>Interdisciplinary Centre for Natural Products, University of Szeged, Eötvös str. 6, H-6720, Szeged, Hungary

## Correspondence

Attila Hunyadi, Institute of Pharmacognosy, Interdisciplinary Excellence Centre, University of Szeged, Eötvös str. 6, H-6720 Szeged, Hungary.  
Email: hunyadi.a@pharm.u-szeged.hu

## Funding information

National Research, Development and Innovation Office, Hungary, Grant/Award Number: K119770; Ministry of Human Capacities, Hungary, Grant/Award Number: 20391-3/2018/FEKUSTRAT; Hungarian Academy of Sciences; UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities

## Abstract

Small molecule, dietary antioxidants exert a remarkably broad range of bioactivities, and many of these can be explained by the influence of antioxidants on the redox homeostasis. Such compounds help to modulate the levels of harmful reactive oxygen/nitrogen species, and therefore participate in the regulation of various redox signaling pathways. However, upon ingestion, antioxidants usually undergo extensive metabolism that can generate a wide range of bioactive metabolites. This makes it difficult, but otherwise a need, to identify the ones responsible for the different activities of antioxidants. By better understanding their ways of action, the use of antioxidants in therapy can be improved.

This review provides a summary on the role of the *in vivo* metabolic changes and the oxidized metabolites on the mechanisms behind the bioactivity of antioxidants. A special attention is given to metabolites described as products of biomimetic oxidative chemical reactions, which can be considered as models of free radical scavenging. During such reactions a wide variety of metabolites are formed, and they can exert completely different specific bioactivities as compared to their parent antioxidants. This implies that

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. *Medicinal Research Reviews* Published by Wiley Periodicals, Inc.

exploring the free radical scavenging-related metabolite fingerprint of each antioxidant molecule, collectively defined here as the scavengome, will lead to a deeper understanding of the bioactivity of these compounds.

Furthermore, this paper aims to be a working tool for systematic studies on oxidized metabolic fingerprints of antioxidants, which will certainly reveal an often-neglected segment of chemical space that is a treasury of bioactive compounds.

#### KEYWORDS

antioxidant mechanism of action, bioactive metabolite, free radical scavenging, oxidative stress, scavengome

## 1 | INTRODUCTION

The field of antioxidants undoubtedly lives its renaissance, largely due to the fact that oxidative stress is closely connected to the development of many chronic diseases, including diabetes, cancer, various aging related and central nerve system (CNS) disorders, etc.<sup>1</sup> Oxidative stress, a term coined by Helmut Sies,<sup>2</sup> has recently been redefined as “a disruption of redox signaling and control”,<sup>3</sup> emphasizing the importance of a dynamic but fine-tuned redox balance in the maintenance of cellular homeostasis.<sup>4–7</sup> Moreover, an intensive reconceptualization of the chemical, biological and pharmacological aspects of oxidative stress and antioxidant defense is ongoing in the field; such perspectives were recently reviewed<sup>8–10</sup> and will not be covered in detail here.

Small-molecule antioxidants have long been considered as compounds able to decrease or, under certain circumstances, contribute to oxidative stress. While their chemical structure makes them able to directly scavenge reactive oxygen and nitrogen species (ROS and RNS, respectively; collectively referred to as RONS),<sup>11</sup> the *in vivo* antioxidant action of these compounds seems to be linked to their potential to interact with various redox signaling pathways by modulation of the activity of redox enzymes.<sup>9,10</sup> Moreover, many dietary antioxidants undergo extensive metabolism; those that are not absorbed in the small intestines can also suffer fragmentation into smaller compounds by gut microbiota. This certainly leads to a situation where the activity observed *in vivo* is necessarily a superposition of the effects of these metabolites on several possible targets.<sup>12,13</sup>

This paper provides a brief summary on the various mechanisms influenced by the activity of small-molecule antioxidants. A set of dietary phenolic compounds including curcuminoids, a stilbene, hydroxycinnamic acid derivatives, a lignan, and a flavonoid are discussed in detail. These are: curcumin (1), demetoxycurcumin (2), bisdemetoxycurcumin (3), resveratrol (4), methyl-*p*-coumarate (5), methyl-cafeate (6), methyl-ferulate (7), secoisolariciresinol (8) and luteolin (9). Selection of these compounds took into consideration their chemical diversity, as well as the fact that they represent classes of natural products whose antioxidant activity attracts particularly high scientific and popular interest. The mechanisms to be discussed include free radical scavenging, modulation of antioxidant/pro-oxidant enzymes and/or transcription factors, and the formation of bioactive metabolites. Mechanisms extensively reviewed elsewhere are touched upon lightly. It is the primary aim of this paper to shed light on the potential biomedical importance of a largely neglected part of the metabolism of antioxidants, the formation of new, bioactive chemical entities upon scavenging ROS or RNS. With this idea in mind, RONS scavenging-related formation of bioactive species from ascorbic acid and estrone are also briefly discussed.

Literature search was conducted using online databases including SciFinder, PubMed, ScienceDirect and Google Scholar. Whenever possible, publications not older than 10 years were favored. However, survey on RONS

scavenging-related oxidative transformation by antioxidants was not limited to a specific time frame. This part of the search focused on biomimetic oxidative transformations of compounds **1-9**, and references were included only if a direct comparison between the bioactivity of the antioxidant and its oxidized analog(s) was available in the same pharmacological model.


## 2 | FREE RADICAL SCAVENGING AND REDOX MODULATION OF ENZYMES AND TRANSCRIPTION FACTORS


Decrease of RONS levels as a result of their scavenging by small-molecule antioxidants had been used as a simplified description of the bioactivity of these molecules, but this point of view has long been outdated. There are many easy-to-perform *in vitro* techniques available for assessing the free radical scavenging capacity of a dietary antioxidant,<sup>11,14-16</sup> and thanks to the simplicity of such bioassays, an abundance of related reports has been published over the last several decades. A large number of studies reported the free radical scavenging activity of the compounds selected for discussion here, and these include curcuminoids,<sup>17</sup> resveratrol,<sup>18-21</sup> cinnamic acids,<sup>11,22,23</sup> lignans,<sup>24</sup> and flavonoids.<sup>11,25,26</sup> Despite the popularity of such antioxidant assays, these have little if any *in vivo* relevance in terms of decreasing RONS levels. Due to the reactivity and short half-life of damaging RONS, it is now generally accepted that dietary antioxidants cannot overcome kinetic limitations in free radical scavenging to make a relevant difference in RONS levels *in vivo*.<sup>9</sup> A possible sole exception is the case of vitamin E that is present in large enough amounts in biological membranes to act efficiently against peroxyl radicals.<sup>27</sup> Nevertheless, it must be noted that, regardless of the low efficiency of this mechanism in preventing cellular damage, RONS scavenging by dietary antioxidants (and/or their metabolites) should take place *in vivo*, and this might still deserve attention from another important perspective, namely the formation of additional metabolites, not as yet studied in detail (see Section 4).

Major ROS with large physiological/pathophysiological importance include hydrogen peroxide ( $\text{H}_2\text{O}_2$ ),<sup>28</sup> superoxide anion radical ( $\text{O}_2^{\bullet-}$ ),<sup>29</sup> hypochlorous acid ( $\text{HOCl}$ ),<sup>30</sup> singlet oxygen ( $^1\text{O}_2$ ),<sup>31</sup> hydroxyl radical ( $^{\bullet}\text{OH}$ ), alkoxyl radical ( $\text{RO}^{\bullet}$ ), and peroxyl radical ( $\text{ROO}^{\bullet}$ ).<sup>32</sup> Major RNS are nitric oxide ( $^{\bullet}\text{NO}$ ), nitrogen dioxide ( $^{\bullet}\text{NO}_2$ ), and peroxynitrite ( $\text{ONOO}^-$ ).<sup>11</sup> Primary RONS, ie  $\text{H}_2\text{O}_2$ ,  $\text{O}_2^{\bullet-}$ , and  $^{\bullet}\text{NO}$ , have relatively low damaging potential, and their levels are under specific enzymatic control.<sup>32,33</sup> Structural damage of macromolecules, associated with oxidative stress and related pathologies, is connected to the more reactive and less regulated, toxic secondary species, mainly  $^{\bullet}\text{OH}$  radical,  $\text{ONOO}^-$  and  $\text{HOCl}$ .<sup>33</sup>

It is generally well accepted that i) the production of RONS is in principle due to enzymatic processes; and ii) the primary counterbalance of the resulting oxidative stress is in fact the pool of antioxidant enzymes and not small-molecule free radical scavengers.<sup>34</sup> Accordingly, *in vivo* relevant antioxidant activity, ie a decrease of oxidative stress by dietary compounds, is a result of the enzymatic modulation of redox equilibrium. ROS are produced primarily by mitochondria (ETC complexes I and II), NADPH oxidases, lipoxygenases (LOXs), cyclooxygenases (COXs), xanthine oxidoreductase (XOR) and cytochrome P (CYP) monooxygenases.<sup>32</sup> Among RNS, the nitrogen-centered radical nitric oxide is produced by nitric oxide synthases (NOSs), and its reaction with  $\text{O}_2^{\bullet-}$  leads to the formation of  $\text{ONOO}^-$ .<sup>32,33</sup> Peroxynitrite can then react with  $\text{CO}_2$  to yield nitrosoperoxycarboxylate ( $\text{ONOOCOO}^-$ ) that further decomposes into  $^{\bullet}\text{NO}_2$  and carbonate radicals. Alternatively, protonation of peroxynitrite yields its acid form ( $\text{ONOOH}$ ), which can undergo homolysis to yield  $^{\bullet}\text{NO}_2$  and  $^{\bullet}\text{OH}$  radicals.<sup>35</sup> Though this latter reaction is less efficient than that between peroxynitrite and  $\text{CO}_2$ , it has been shown to occur and have biological significance if peroxynitrite is formed and may affect proton pumps of the cell membrane.<sup>36</sup>

Antioxidant enzymes counterbalance the potentially harmful effects of RONS. These can exert their function directly, such as for example superoxide dismutases (SODs), glutathione peroxidase (GPx) and catalase (CAT), or indirectly, such as for example glutathione-S-transferases (GSTs), UDP-glucuronosyl transferases, and NADP





**FIGURE 2** (A) Metabolites of resveratrol (**4**) identified from *in vitro* and *in vivo* studies. Bioactivity of these metabolites is discussed in Section 3.2. Glu: glucuronidyl. (B) Some oxidized derivatives of resveratrol obtained from biomimetic oxidative chemistry that had bioactivity profile different from that of their parent compound, see Section 4.2 and Table 1. These compounds may likely form through free radical scavenging


quinone oxidoreductase. The role of these enzyme systems in oxidative stress has extensively been reviewed by others.<sup>34,37,38</sup>

It is now also well known that certain types of ROS (eg H<sub>2</sub>O<sub>2</sub>) and RNS (eg •NO and ONOO<sup>−</sup>) play a pivotal signaling role. This might occur through the reversible oxidation of proteins on the SH groups of cysteine and/or methionine, and in particular, S-sulfenylation, S-glutathionylation, S-nitrosylation, S-polysulfidation or disulfide bond formation, and/or nitration of tyrosine and tryptophan residues. MAPK-mediated pathways including ERK1/2, p38 and JNK, PI3K/Akt signaling, and several transcription factors such as Nrf2, AP-1, NF-κB, HIF-1α, p53, Wnt/β-catenin, that control the expression of a large number of genes, are known to be under redox regulation. For more details on this subject and most recent developments in the field, see the review by Moldogazieva et al.<sup>7</sup>

Accordingly, it is not surprising that many dietary antioxidants have been reported to interfere with a variety of the above-mentioned pathways/transcription factors, and such interactions appear to play an important role in the polypharmacology of these compounds.<sup>39</sup> Briefly, it seems an important common feature of polyphenol compounds to induce an adaptive response to oxidative stress through the activation of Nrf2.<sup>9</sup> This leads to the upregulation of antioxidant enzymes including CAT, GPx, GST, paraoxonases (PONs), glutathione reductase (GR), and γ-glutamyl cysteine synthetase (γ-GCS).<sup>39</sup> Many plant polyphenols also share an ability to down-regulate PI3K/Akt,<sup>40</sup> activate AMPK<sup>41–43</sup> and sirtuins,<sup>43–46</sup> and suppress NF-κB signaling.<sup>47</sup> These redox-regulated pathways have also been implicated as underlying mechanisms for the health-promoting and lifespan-increasing effects of dietary polyphenols.<sup>48</sup>

### 3 | METABOLISM OF ANTIOXIDANTS IN VIEW OF THEIR BIOACTIVITY

While there is an abundance of *in vitro* pharmacological studies on dietary antioxidants, promising results obtained in such experimental systems are difficult to translate into *in vivo* applications. A major reason for this is the poor oral bioavailability of such compounds, which is largely due to their metabolism by gut microbiota and/or the




**FIGURE 3** (A) Metabolites of methyl hydroxycinnamates (5-7) identified from *in vitro*, *in vivo* and *ex vivo* studies. Bioactivity of these metabolites is discussed in Section 3.3. Glu: glucuronidyl. Due to the methylation of **6** by catechol-O-methyltransferase (COMT), overlaps are observed for compounds **6** and **7**, i.e. **6b** and **7a** are metabolites of **7** and **6**, respectively. Metabolites **6h-6k** were obtained through cleavage of chlorogenic acid to **6a** by gut microbiota. (B) Some oxidized derivatives of **5-7** obtained from biomimetic oxidative chemistry that had bioactivity profiles different from that of their parent compounds, see Section 4.3 and Table 1. These compounds may likely form through free radical scavenging

intestinal mucosa, and the subsequent extensive metabolism of the absorbed fraction mostly within the liver and kidneys. The microbial metabolism of ingested polyphenols involves enzymatic hydrolysis of  $\beta$ -glycosidic bonds liberating aglycons that are absorbed better than their glycosides. Microbial metabolism frequently leads to a variety of smaller fragments, including simple phenolic acids, phloroglucinol derivatives, etc. Detailed reviews on

To facilitate comparison between metabolites described in Sections 3 and 4, the corresponding Figures 1A-5A will present previously identified phase I and II metabolites of compounds **1-9**, and Figures 1B-5B metabolites obtained by biomimetic oxidative chemistry discussed in Section 4.

The diarylheptanoid antioxidants from *Curcuma* species (turmeric: *C. longa*, wild turmeric: *C. aromatica*, Javanese turmeric: *C. xanthorrhiza*), curcumin (**1**), demethoxycurcumin (**2**) and bisdemethoxycurcumin (**3**) (Figure 1), have achieved important scientific and clinical interest. At the time of this writing, 57 current clinical studies on curcumin (**1**) at various stages are registered at the National Institutes of Health (NIH) database. A wide range of *in vitro* and *in vivo* studies have claimed beneficial bioactivities attributed to curcumin (**1**), and these bioactivities include chemo-preventive, neuroprotective, antitumor and anti-mutagenic, antimetastatic, Antiangiogenic, immunomodulatory, anti-inflammatory, etc., and are extensively reviewed by others.<sup>17,53-57</sup>

**FIGURE 4** (A) Metabolites of secoisolariciresinol (**8**) identified from *in vitro* and *in vivo* studies. Bioactivity of these metabolites is discussed in Section 3.4. Glu: glucuronidyl, SDG: diglucoside of **8**. In case of asymmetric conjugates of **8b** and **8c**, identification was based on mass spectrometry, hence the differently substituted phenolic rings may be interchangeable.<sup>106,107</sup> (B) Some oxidized derivatives of **8** obtained from biomimetic oxidative chemistry that had bioactivity profiles that differed from that of their parent compound, see Section 4.4 and Table 1. These compounds may likely form through free radical scavenging. Lariciresinol (**8g**) is also a naturally occurring lignan that may be metabolized by gut microbiota to **8**, and subsequently to **8a-8c**.



**FIGURE 5** (A) Metabolites of luteolin (**9**) and its glycosides identified from *in vitro* and *in vivo* studies. Bioactivity of these metabolites is discussed in Section 3.5. COMT: catechol-O-methyltransferase, Glu: glucuronidyl, UDP-GluT: UDP-glucuronosyltransferase. The formation of phloroglucinol (**9o**) has been suggested based on the presence of dihydrocaffeic acid (**9p**). (B) Specific oxidized derivatives of **9** that were identified from biomimetic oxidative chemistry and are well-known to form through free radical scavenging. Glutathione-S-transferase inhibitory activity **9q** and **9r** in comparison with that of **9** is discussed in Section 4.5 and summarized in Table 1

It is well understood that curcumin has very low bioavailability and low chemical stability.<sup>58</sup> For example, oral administration of an amount as high as 500 mg/kg of curcumin to streptozotocin-induced diabetic rats results in a maximum of only 0.06 µg/mL plasma concentration, which represents an oral bioavailability of ca. 0.5%.<sup>59</sup> Therefore, metabolites and decomposition products of curcumin and its analogs are thought to play a central role in their remarkable polypharmacology.<sup>56,60,61</sup>

Structures of the known metabolites of curcuminoids (**1-3**) identified from *in vivo* (mice, rats, or humans) and *ex vivo* (tissue slices) studies, as well as those from fermentation with gut microbiota, are presented in Figure 1A as compounds **1a-1r**, **2a-2r**, and **3a-3k**. The biotransformation of curcuminoids is known to involve reduction (a major metabolic step by gut microbiota<sup>62,63</sup> and by the liver<sup>64,65</sup>), demethylation and/or further hydroxylation, cyclization (by gut microbiota<sup>62</sup>), and the formation of glucuronide and/or sulfate conjugates primarily at phenolic OH groups (accordingly, **1d** is a minor metabolite).<sup>64-68</sup> Sulfate conjugation of curcumin (**1**) was recently also demonstrated to take place in breast cancer cells, and rapid excretion of its conjugates took place through a yet unidentified efflux transporter, possibly ABCG2.<sup>69</sup> As previously mentioned, free, unchanged curcumin appears to be scarcely present in the peripheral blood and tissues after oral ingestion.<sup>66</sup> When administered intravenously in mice, it has a half-life of around 30 minutes.<sup>70</sup> The main hepatic metabolite of curcumin (**1**) in humans and rats was found to be hexahydrocurcumin (**1a**) that can further be reduced to octahydrocurcumin, also referred to as curcuminol (**1b**).<sup>64</sup> Moreover, at least in rats, phase I metabolism can involve further reduction and methoxylation of the heptyl chain (forming **2l** and **2n**), as evidenced by the isolation of demethoxycurcumin metabolites (**2k-2q**) from rat feces and urine.<sup>71</sup>

The reduction and/or conjugation certainly influences the bioactivity of curcumin. In terms of affecting COX-2 expression, these metabolic changes may represent bio-inactivation.<sup>64</sup> The reduced metabolites tetra-, hexa-, and



octahydrocurcumin (**1m**, **1a**, and **1b**, respectively) are also less active than curcumin as inhibitors of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and NF- $\kappa$ B activation in RAW 264.7 macrophages.<sup>72</sup> However, Lee et al found that hexahydrocurcumin (**1a**) exerts potent anti-inflammatory activity by inhibiting LPS-induced, COX-2 derived prostaglandin E<sub>2</sub> production in RAW264.7 cells with an IC<sub>50</sub> value of 0.7  $\mu$ M.<sup>73</sup> Although in this study curcumin (**1**) was unfortunately not used as a control, Mohd Aluwi et al found it to act with an IC<sub>50</sub> value of ca. 16  $\mu$ M.<sup>74</sup> Therefore, it seems that hexahydrocurcumin (**1a**) is more potent in this regard than its parent compound, although no direct comparison was made in this case. A broad range of further bioactivities of hexahydrocurcumin (**1a**) shows that this compound is a potent bioactive metabolite of curcumin (**1**) and this has been recently reviewed by Huang et al.<sup>75</sup> A number of studies demonstrated that the *in vitro* antioxidant activity of **1a** is at least comparable to that of curcumin as scavenger of DPPH,  $\cdot$ NO, and  $\cdot$ OH radicals, and as inhibitor of AAPH-induced linoleic oxidation and hemolysis.<sup>76–78</sup> Hexahydrocurcumin (**1a**) was also reported as a potent antioxidant *in vivo* such that a single intraperitoneal injection of 10 to 40 mg/kg dose significantly decreased the MDA and  $\cdot$ NO levels and the expression of NF- $\kappa$ B and COX-2 in a rat stroke model. This same study found **1a** to protect the rats' brain from ischaemia/reperfusion injury, and to reduce inflammatory response.<sup>79</sup> Curcumin was also studied and found effective in a similar rat model, however at a much larger dose (300 mg/kg).<sup>80</sup> Unfortunately, this makes it difficult to draw any comparison between the efficacies of the two compounds. Nevertheless, there is no doubt of the importance of the activity of metabolite **1a** *in vivo*. Most recently, this compound was also found to efficiently inhibit corneal neovascularization, an important reason for corneal blindness, induced by the p-bFGF- $\alpha$ 1-18 & p-VEGF- $\alpha$ 1-18 complex in an *in vivo* rat model, and it exerted ca. 50% inhibition after 6 days at a dose of 1  $\mu$ g.<sup>81</sup>

### 3.2 | Metabolism of resveratrol

Resveratrol (**4**; Figure 2) is probably the most popular dietary antioxidant. This stilbene is best known as the “magic” constituent of blue grape skin and red wine, and it occurs in lower amounts in several foods including a variety of berries (eg cranberry, mulberry), tomato skin, peanuts, pistachios, cocoa, etc.<sup>82</sup> Resveratrol (**4**) offers a broad spectrum of health benefits including its widely accepted cardiovascular protective effect and its ability to reduce cancer risk, even though the related literature is very diverse and not fully conclusive as to its real value.<sup>83</sup>

The pharmacokinetics and metabolism of resveratrol (**4**) has most recently been reviewed by Wang & Sang.<sup>84</sup> Despite its rapid absorption, the extensive and fast metabolism makes the bioavailability of resveratrol extremely low. Oral ingestion of as high as 5 g of resveratrol by humans was found to lead to peak plasma concentrations of ca. 2.4  $\mu$ M, while resveratrol-3-O-sulfate (**4c**; Figure 2A) could reach 8 times higher concentration and over 20 times higher AUC value.<sup>85</sup> Major metabolic transformations of resveratrol involve phase II and include glucuronide and/or sulfate conjugation, leading to metabolites **4a** to **4i**, and reduction by gut microbiota to form compounds **4j** to **4l**.<sup>84</sup> Conjugation takes place in the intestinal mucosa and liver, and the sulfate conjugate **4c** was also identified to form in adipocytes.<sup>86</sup> Relative importance of the different conjugation routes shows dose-dependency. Administration of smaller, 5 to 50 mg doses of resveratrol (**4**) led to the appearance of glucuronides as main metabolites in the plasma of human volunteers. In contrast, when larger,  $\geq$  250 mg doses were administered, the sulfate conjugate **4c** was observed as the major metabolite.<sup>84</sup>

Conjugation significantly alters the bioactivity profile of resveratrol in a way that some activities decrease or disappear, while others are at least partially retained.<sup>87,88</sup> The Na<sup>+</sup> salts of compounds **4i** and **4h** are much weaker inhibitors of NF- $\kappa$ B, COX-1, and COX-2, as well as of the  $\cdot$ NO production of LPS-stimulated RAW 264.7 macrophages as compared to resveratrol. However, the Na<sup>+</sup> salt of compound **4c** and the K<sup>+</sup> salt of compound **4d** showed COX-1 inhibition (IC<sub>50</sub> = 3.60 and 7.53  $\mu$ M, respectively) comparable to that of their parent compound (IC<sub>50</sub> = 6.65  $\mu$ M). Both of these metabolites exerted a similarly strong inhibition of COX-2, i.e. they lost the selectivity of resveratrol towards COX-2 that is about 10 times (IC<sub>50</sub> = 0.75  $\mu$ M).<sup>88</sup> As an interesting change in bioactivity due to metabolism, compound **4c** was found to exert a selective antiestrogen effect on estrogen

receptor  $\alpha$  in a transformed yeast model and also in MCF-7 cells. Resveratrol acted as a partial agonist in this study.<sup>89</sup> Resveratrol 3-glucuronide (**4b**) and 3-sulfate (**4c**) conjugates also play an important role in tissue accumulation. Following a 6 weeks-long intraperitoneal daily treatment of streptozotocin-induced diabetic rats with 5 mg/kg of resveratrol (**4**), conjugates **4b** and **4c** were found to accumulate in the heart but not in the pancreas tissue. Importantly, concentrations of **4c** (reaching a maximum of 20 nM) positively correlated with the improvement of cardiac function and haemodynamic performance.<sup>90</sup> It is worth noting that since deconjugation can also take place, the circulating conjugates can as well be considered as a pool of resveratrol to release in certain tissues.<sup>83,84</sup>

### 3.3 | Metabolism of hydroxycinnamates

Hydroxycinnamic acids are among the most abundant dietary antioxidants, present in many vegetables, fruits, cereals and beverages.<sup>91</sup> These compounds can occur in plants either in free form, or as conjugates (eg as esters in chlorogenic acids, rosmarinic acid, etc.), and they are also well known as structural elements in the biosynthesis of many plant phenolic compounds such as lignans or flavonoids.<sup>23,91-93</sup>


After oral ingestion, enteral metabolism of methyl esters of *p*-coumaric, caffeic and ferulic acids (compounds **5**, **6**, and **7**, respectively; Figure 3) involves de-esterification<sup>94</sup> and primarily sulfate or, to a lesser extent, glucuronide conjugation, leading to the formation of compounds **5a-5d**, **6a-6g**, and **7a-7c**, respectively (Figure 3A).<sup>95</sup> In case of the catechol methyl caffeate (**6**) and its metabolite caffeic acid (**6a**), methylation by catechol-O-methyltransferase (COMT) also takes place, with subsequent formation of the sulfate conjugates of ferulic acid (**6b**) and isoferulic acid (**6d**) as main products.<sup>94-96</sup> Following absorption, glucuronidation, methylation and/or sulfation takes place in the liver and the formed metabolites participate in enterohepatic circulation. Methylation by COMT was also observed in the kidneys.<sup>92</sup> Extrapolating from results obtained for chlorogenic acid (5-O-caffeoylquinic acid), it is also clear that bacterial metabolism of caffeic acid involves side-chain saturation as a major step (forming **6h**), and that it can also be dehydroxylated and undergo gradual side-chain shortening all the way down to benzoic acid (forming **6g** and **6i-6k**).<sup>97,98</sup> Similar metabolic transformations are expected for compounds **5** and **7**, as well.

Unsurprisingly, the bioactivity profiles of methylated, glucuronidated and sulphated metabolites of hydroxycinnamic acids show significant differences as compared with those of their parent compounds.<sup>92</sup> The *in vitro* antioxidant activities such as ferric reducing activity and 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging, as well as the antibacterial activity of the methylated and/or conjugated metabolites typically decrease as compared to their corresponding parent compounds. However, some activities are at least partially retained. Heleno et al found that the acyl glucuronidated derivatives of compound **5a** and those of its expectable metabolite *p*-hydroxybenzoic acid exert stronger cytotoxicity on some human cancer cell lines than their parent antioxidant.<sup>99</sup> It should be noted that these compounds were of synthetic origin and the metabolism-related formation of acyl glucuronides has not been reported for compounds **5-7** nor for their demethylated forms.

### 3.4 | Metabolism of secoisolariciresinol

Secoisolariciresinol (**8**; Figure 4) is a lignan present in largest amounts in its diglycoside (SDG) form in flax (*Linum usitatissimum* L.) seed, and it is widely acknowledged for its health benefits in preventing many lifestyle-associated problems, including cardiovascular disease and metabolic syndrome, and it also appears to have chemopreventive activity against cancer, particularly colorectal cancer.<sup>100-102</sup>

Secoisolariciresinol (**8**) is a classic example for a compound where transformation by gut microbiota is crucial for the formation of major bioactive metabolites, so called mammalian lignans or enterolignans, particularly enterodiols (**8b**) and enterolactones (**8c**); for chemical structures, see Figure 4A. These compounds are efficiently absorbed in humans<sup>103</sup> and seem to play a significant role in the health-preserving effect attributed to flax seed consumption.<sup>104</sup> In healthy postmenopausal women, 86 or 172 mg single oral dose of an extract containing 43%



**FIGURE 6** Cyclic antioxidant mechanism for estrone and estradiol, involving a chemically stable, *p*-quinol intermediate formed through  $\cdot\text{OH}$  radical scavenging. DHED was successfully applied *in vivo* as a brain-targeted neuroprotective pro-drug of estradiol<sup>147–149</sup>

SDG (ie 37 or 74 mg SDG) resulted in peak plasma concentrations of ca. 250 or 540 ng/mL (**8**), 35 or 75 (**8b**) and 40 or 50 ng/mL (**8c**).<sup>103</sup> Subsequent to bacterial deglycosilation, demethylation, and dehydroxylation of SDG (and lactone ring formation in case of **8c**),<sup>105</sup> **8b** and **8c** undergo phase II metabolism during absorption by colon epithelial cells to form sulfate and glucuronide conjugates (**8ba–8be** and **8cg–8ck**).<sup>106,107</sup> The free, nonconjugated fractions of both **4b** and **4c** undergo microsomal oxidative metabolism in the liver, leading to hydroxylated products at the aromatic rings (**8bf–8bh** and **8ca–8cf**) or in the aliphatic region.<sup>108,109</sup> Structures of the latter metabolites, however, have not been unequivocally identified, hence they are not presented here.

The enterolignans **8b** and **8c** are well-known for their bioactivity.<sup>110</sup> Briefly, they are antioxidants themselves, and act as phytoestrogens both at the receptor level and through competing with endogenous steroid hormones for plasma protein binding. In addition, **8c** also inhibits key enzymes of the human steroid metabolism including aromatase,<sup>111</sup> 5 $\alpha$ -reductase,<sup>112</sup> cholesterol-7 $\alpha$ -hydroxylase<sup>110</sup> and 17 $\beta$ -hydroxysteroid dehydrogenase.<sup>113</sup> Epidemiological evidence suggests the preventive role of **8b** and **8c** in breast and prostate cancer,<sup>110</sup> and several recent *in vitro* and *in vivo* studies imply their positive effect in a variety of cancers including ovarian,<sup>114</sup> colorectal,<sup>115</sup> and lung cancer.<sup>116</sup> However, while **8b** and **8c** have extensively been studied, little is known on the bioactivity of their further metabolites.

### 3.5 | Metabolism of luteolin

Luteolin (**9**; Figure 5) is a catechol-type B-ring containing flavone, present in many fruits, vegetables and medicinal plants, and valued for a wide range of health benefits including anti-inflammatory, neuro-protective and chemo-preventive effects as detailed in the reviews by Kwon<sup>117</sup> and Aziz et al,<sup>118</sup> and the recent book by Dwight.<sup>119</sup>

In healthy human subjects, a single-dose oral intake of 20 mg/kg of luteolin resulted in a peak plasma concentration of ca. 330 ng/mL at 1 hour after administration,<sup>120</sup> suggesting that bioactivities observed *in vitro* at around 0.1–1  $\mu\text{M}$  concentrations might have *in vivo* relevance. As to its metabolic fate, several recent studies addressed the metabolism of luteolin (**9**) in cell cultures and/or after oral ingestion in rodents.<sup>121–123</sup> Luteolin (**9**) is absorbed faster in the small than in the large intestine, and undergoes a significant intestinal first-pass metabolism through conjugation to mono- and diglucuronides (**9a–9d**, **9k–9m**) by UDP-glucuronosyltransferases,<sup>121</sup> and, in parallel to this, O-methylation by COMT forms chrysoeriol (**9e**) and diosmetin (**9f**) that are then glucuronidated as is the parent compound<sup>123</sup> (chemical structures are presented in Figure 5A). Administering a single 20  $\mu\text{M}$ /kg oral dose in rats, tissue distribution of luteolin (**9**) and its metabolites **9b–9g**, **9i** and **9j** was found to be rapid into the organs, with the exception of **9e** and **9j** whose presence was not detectable in the brain at any time probably due to the blood-brain barrier. In most tissues, the 3'-glucuronide conjugate (**9c**) was the predominant metabolite reaching peak concentrations of ca. 2.5 nM/g in the small intestine, ca. 0.7 nM/g in the lungs, and ca. 0.5 nM/g in the stomach, liver and kidney, and the peak plasma concentration was ca. 1.5 nM/mL. In contrast, luteolin (**9**) itself reached only a

0.6 nM/mL peak plasma concentration in that study, and its concentration in the organs was also typically below that of **9c**.<sup>124</sup> Unlike luteolin, its glycosides reach the large intestine where the sugar moieties can efficiently be cleaved by gut bacteria. Subsequent bacterial metabolism of luteolin involves the reduction of the 2,3-double bond to form the flavanone eriodictyol (**9n**) whose cleavage to phloroglucinol (**9o**) and 3-(3,4-dihydroxyphenyl)propionic acid (**9p**) can also take place.<sup>125</sup>

Concerning the bioactivity of luteolin metabolites, the anti-inflammatory activity of three major monoglucuronide conjugates (**9b–9d**) was recently studied in comparison with that of their parent compound in LPS-treated RAW264.7 cells. At 25  $\mu$ M, luteolin (**9**) could completely prevent the LPS-induced increase in the mRNA expression of *IL-6*, *IL-1 $\beta$* , *NF- $\kappa$ B1*, *Ccl2*, *Ccl3* and *Ccl5*. While the main metabolite **9c** was inactive at the same concentration, **9a** and particularly **9b** were found to partially retain the activity of their parent compound, with **9b** acting ca. half as strong as luteolin (**9**).<sup>126</sup> Considering the concentrations that can be achieved *in vivo*, compounds acting weak at 25  $\mu$ M concentration might seem to have low chance to exert a relevant *in vivo* activity. However, evidence suggests that a microenvironment-dependent deconjugation can also take place: an unspecified monoglucuronide of **9**, most likely **9c**, was found to be hydrolyzed to free luteolin by human  $\beta$ -glucuronidase released by neutrophils.<sup>127</sup> This can largely influence the bioactivity of circulating luteolin conjugates during inflammation processes.<sup>128</sup>

## 4 | BIOLOGICAL SIGNIFICANCE OF RONS SCAVENGING-RELATED ANTIOXIDANT METABOLITES

The structure and function of antioxidants changes upon RONS scavenging. It needs to be stressed that the sensitive chemical structures of these compounds make them subjects not only to reversible redox circles, but their oxidation can clearly result in chemically stable metabolites as well. Moreover, this can take place not only due to well-controlled enzymatic oxidation for example through the CYP450 system, but it is also possible through RONS scavenging. For example, the relatively stable RNS peroxynitrite (ONOO<sup>−</sup>; first half-life at pH = 7.2 is ca. 2.2 seconds<sup>129</sup>) can not only oxidize but also hydroxylate and nitrate phenolic rings<sup>130,131</sup> leading to stable products that cannot be changed back into their parent compounds through a simple reduction. While the scavenging itself has little chance to significantly decrease RONS levels, the forming oxidized species need to be considered as part of the locally-forming metabolite-fingerprint in the biological compartment where this takes place.

Studies reviewed in this Section suggest that due to their altered 3D chemical structure as compared to that of the parent antioxidant, it is reasonable that any such metabolites have the potential to interfere with other signaling pathways, enzymes, receptors or cell machinery, i.e. their ROS/RNS-dependent formation will have an impact on the observed bioactivity. Moreover, the ensuing bioactivity must not be limited to redox processes and related signaling pathways, but any druggable target has the chance of being involved. It is also worth noting that since the commonly observed polypharmacology of antioxidants is a result of a superposition of a wide variety of mechanisms including those affected by the bioactive metabolites, any stable, individual metabolite should likely act in a more specific way than its parent compound. The below-discussed vitamin C and estrone provide good examples to demonstrate the biological relevance of this phenomenon.

It is of particular interest that the oxidized form of vitamin C, dehydroascorbic acid (DHA) was identified as a specific inhibitor of I $\kappa$ B $\alpha$  Kinase  $\beta$  (IKK $\beta$ ) and IKK $\alpha$ , regulators of the transcription factor NF- $\kappa$ B.<sup>132</sup> NF- $\kappa$ B plays an important and complex role in stress, immune response, cell death and survival, and ROS have an activating effect on IKK $\beta$ .<sup>133</sup> As such, vitamin C plays a dual role in modulating these pathways, both pointing in the same direction. On the one hand, ascorbic acid acts as an antioxidant decreasing ROS levels (hence decreasing their potential to activate IKK $\beta$ ), while DHA, formed through ROS scavenging, specifically inhibits the above-mentioned kinase.<sup>132</sup> The activation pathways of NF- $\kappa$ B, including the IKK kinases, are considered as emerging antitumor targets,<sup>134</sup> but the very high number of pro- or antiapoptotic genes<sup>135</sup> controlled by NF- $\kappa$ B makes the overall picture complex.

**TABLE 1** Comparison of the bioactivities of antioxidants (AO) **1-9** and their oxidized metabolites (OM) obtained from biomimetic oxidative chemistry. Chk1/Chk2: Checkpoint kinases 1 and 2, CR: cross-resistance, dox: doxorubicin, L5178<sub>B1</sub>: L5178 cells transfected with the human ABCB1 transporter, NCI-H460<sub>Dox</sub>: NCI-H460 cells adapted to dox, Topo II: topoisomerase II, XO: xanthine oxidase.

A-O	Bioactivity of			
	Oxidizing agent	OM	Bioactivity target	AO
1	K <sub>3</sub> Fe(CN) <sub>6</sub>	Reactive intermediates	Topo II	Inactive at 50 μM <sup>164</sup>
	O <sub>2</sub> (autooxidation)	<b>1z, 1za, 1zb, 1zc, 1ze</b>	XO	Experimental: conflicting <sup>170,171</sup> <i>In silico</i> : K <sub>d</sub> = 141 (keto) or 186 μM (enol) <sup>166</sup>
	O <sub>2</sub> (autooxidation)	<b>1z, 1za, 1zb, 1zd, 1ze</b>	CYP450 enzymes	CYP1A2, CYP3A4, CYP2D6, CYP2C9, CYP2B6 IC <sub>50</sub> = 40.0, 16.3, 50.3, 4.3, and 24.5 μM <sup>169</sup>
2	K <sub>3</sub> Fe(CN) <sub>6</sub>	Reactive intermediates	NF-κB	IC <sub>50</sub> = 18 μM; depends on autooxidation rate <sup>167</sup>
	K <sub>3</sub> Fe(CN) <sub>6</sub>	Reactive intermediates	Topo IIα	Inactive at 25 μM, 2-fold relative DNA cleavage at 50 μM <sup>165</sup>
	K <sub>3</sub> Fe(CN) <sub>6</sub>	Mixture at 33% conversion	Hydroperoxidase activity of LOX	Inactive at 100 μM <sup>180</sup>
3	FeCl <sub>3</sub> or CuCl <sub>2</sub>	<b>4m</b>		IC <sub>50</sub> = 17 μM <sup>180</sup>
	FeCl <sub>3</sub> or DPPH	<b>4n</b>		IC <sub>50</sub> = 62 μM <sup>180</sup>
	PIFA	<b>5f</b>	Cancer cell viability	Very weak on a diverse cell line panel; strong CR with Dox; L5178 IC <sub>50</sub> = 125 μM
5	PIFA or FeSO <sub>4</sub> + H <sub>2</sub> O <sub>2</sub>	<b>5e</b>		L5178 <sub>B1</sub> IC <sub>50</sub> > 150 μM NCI-H460 IC <sub>50</sub> = 120 μM NCI-H460 <sub>Dox</sub> IC <sub>50</sub> = 1043 μM <sup>183</sup>
				No CR with Dox; L5178, L5178 <sub>B1</sub> IC <sub>50</sub> = 0.46 and 0.62 μM; NCI-H460, NCI-H460 <sub>Dox</sub> IC <sub>50</sub> = 1.85 and 2.06 μM <sup>183</sup>
				Weak CR with Dox; L5178, L5178 <sub>B1</sub> IC <sub>50</sub> = 5 and 12 μM; NCI-H460, NCI-H460 <sub>Dox</sub> IC <sub>50</sub> = 3.8 and 7 μM <sup>183</sup>
6				Relative DNA cleavage at 5 μM 3-fold (Topo IIα) or 2-fold (IIβ) <sup>164</sup>
				<i>In silico</i> : <b>1z, 1za, 1zb, 1zc, and 1ze</b> : K <sub>d</sub> = 4.57, 70.8, 24.0, 91.2, and 97.7 μM, respectively <sup>170</sup>
				<b>1zb</b> CYP1A2 and CYP2B6: IC <sub>50</sub> = 228 and 260 μM, all others > 300 μM <sup>169</sup>
7				Stable oxidation products less potent; intermediates covalently bind to IKKβ at Cys179 <sup>167</sup>
				2-Fold relative DNA cleavage at 25 μM <sup>165</sup>
				1.5-Fold relative DNA cleavage at 10 μM <sup>165</sup>
8				98% Inh. at 50 μM <sup>180</sup>
				IC <sub>50</sub> = 17 μM <sup>180</sup>
				IC <sub>50</sub> = 62 μM <sup>180</sup>
9				Very weak on a diverse cell line panel; strong CR with Dox; L5178 IC <sub>50</sub> = 125 μM
				L5178 <sub>B1</sub> IC <sub>50</sub> > 150 μM NCI-H460 IC <sub>50</sub> = 120 μM NCI-H460 <sub>Dox</sub> IC <sub>50</sub> = 1043 μM <sup>183</sup>
				No CR with Dox; L5178, L5178 <sub>B1</sub> IC <sub>50</sub> = 0.46 and 0.62 μM; NCI-H460, NCI-H460 <sub>Dox</sub> IC <sub>50</sub> = 1.85 and 2.06 μM <sup>183</sup>

(Continues)

TABLE 1 (Continued)

A-O	Oxidizing agent	OM	Bioactivity target	Bioactivity of	
				AO	OM
6	PIFA or FeSO <sub>4</sub> + H <sub>2</sub> O <sub>2</sub>	5e	Chk1/Chk2	Inactive at 10 $\mu$ M <sup>183</sup>	Chk1-S345pI, Chk2-T68pI at 10 $\mu$ M <sup>183</sup>
	Ag <sub>2</sub> O	6l	Cancer cell viability	Contradictory on MCF-7: IC <sub>50</sub> ca. 100 $\mu$ M <sup>184</sup> or 0.62 $\mu$ M <sup>185</sup>	MCF-7: IC <sub>50</sub> = 29 nM; MDA-MB-435, MDA-N, BT-549 IC <sub>50</sub> < 10 nM <sup>186</sup>
	Ag <sub>2</sub> O	6l	Angiogenesis	Inactive in zebrafish <sup>190</sup>	(2R,3R) Antiangiogenic at 5 $\mu$ g per pellet in chorioallantoic membrane assay <sup>188</sup>
7	Ag <sub>2</sub> O or <i>Trametes versicolor</i> laccase	7d	Angiogenesis	In ECV304 cells proangiogenic: Cyclin D1 and VEGF↑ at 0.1–10 $\mu$ g/mL <sup>191</sup> ; or Antiangiogenic: *NO ↓, VEGF↓ at 20–80 $\mu$ M <sup>192</sup>	Antiangiogenic on aortic endothelial cells, and VEGF ↓ in swine granulosa cells, both at 1 $\mu$ M <sup>190</sup>
8	AIBN in ethyl linoleate / ACN <sup>193</sup>	8g	NO production of LPS-activated BV-2 cells	IC <sub>50</sub> = 87.62 $\mu$ M <sup>196</sup>	IC <sub>50</sub> = 51.80 $\mu$ M <sup>196</sup>
		8g	Adipocyte differentiation, fat accumulation	Inhibition at IC <sub>50</sub> > 100 nM <sup>197</sup>	Inhibition at IC <sub>50</sub> < 10 nM <sup>197</sup>
9	Tyrosinase, with or without the presence of GSH	9q	Human placenta GST $\pi$	Inactive at 25 $\mu$ M, 90% inh. at 100 $\mu$ M; mixed mode inh. (K <sub>i</sub> = 53 $\mu$ M, K <sub>i</sub> ' = 97 $\mu$ M) <sup>b 199</sup>	85%–90% Inh. at 10–20 $\mu$ M; irreversible mixed mode inh. (K <sub>i</sub> = 20 nM, K <sub>i</sub> ' = 50 nM) <sup>199</sup>
		9r			88%–95% Inh. at 5–25 $\mu$ M; reversible competitive inh. (K <sub>i</sub> = 0.74 $\mu$ M) <sup>199</sup>

<sup>a</sup>Estimated values.<sup>b</sup>GST  $\pi$  inhibition was determined by the CDNB method; data in the table refer to results obtained with respect to GSH, K<sub>i</sub> and K<sub>i</sub>': inhibition constants for the inhibitor-enzyme and inhibitor-(enzyme-substrate complex) bindings, respectively.

For example, vitamin C was found to exert an antagonistic effect on the cytotoxic activity of several antineoplastic drugs, and the antagonism was much stronger than that expected from the weak decrease in ROS levels.<sup>136</sup> On the other hand, large doses of vitamin C were recently found to selectively kill *KRAS* or *BRAF* mutant colorectal cancer cells, and this activity was rather connected to DHA, not ascorbic acid.<sup>137-139</sup> This is an important finding since *KRAS* and *BRAF* are major oncoproteins in the gastrointestinal tract, and their mutation is closely connected with the progression and therapy resistance of colon cancer.<sup>140</sup> Whether or not, and if yes, to what extent IKK inhibition by DHA plays a role in the above, remains unknown. Another interesting example to the possible pharmacological importance of DHA is the antiviral activity of vitamin C. DHA was reported to have a much stronger antiviral activity as compared to that of ascorbic acid against Herpes simplex virus 1 (HSV-1).<sup>141</sup> Based on the weaker cytotoxicity observed with DHA than with ascorbic acid, Furuya et al concluded that the antiviral effect of DHA is unlikely to arise due to an effect on the host cells.<sup>141</sup> However, HSV-1 replication is highly NF- $\kappa$ B dependent and IKK inhibition can greatly reduce virus yield through inhibition at the transcription level,<sup>142,143</sup> exactly as found in the above-mentioned study.<sup>141</sup> As an important consequence of this possible mechanism of action for the antiviral activity of DHA, one could conclude that IKK inhibition by DHA matters enough to make relevant the pharmacological differences between the two forms of vitamin C. In other words, it would mean that oxidative stress directly modulates the specific bioactivity of this antioxidant through its metabolite.

Another good example for the biological relevance of a compound emerging from RONS scavenging by an antioxidant is the Prokai cycle of estrone and estradiol that explains their neuroprotective activity. Prokai et al found that  $\cdot$ OH radical scavenging by estrone yields a *p*-quinol A-ring-containing intermediate that subsequently undergoes a NADP-dependent enzymatic reduction back to estrone, without contributing to oxidative stress on its own but becoming able to scavenge further radicals.<sup>144-146</sup> *In vivo* administration of the analogous *p*-quinol derivative of estradiol (DHED) demonstrated no estrogenic activity, and it was rapidly taken up into the brain where it initiated the above-mentioned redox cycle; therefore it acted as a targeted neuroprotective agent without any apparent systemic side-effects.<sup>147-150</sup> On one hand, this provides an attractive strategy to deliver estrogens to the brain through their pro-drugs. On the other hand, it also represents a good example for a phenolic antioxidant (estradiol or estrone) to be transformed to a metabolite (eg DHED) on a free radical scavenging-related manner. Certainly, such a nonaromatic metabolite will have a significantly different bioactivity profile than its parent compound (ie no estrogenic effect in this case; other specific bioactivities were not studied). The reaction mechanism for the above-mentioned redox cycle is shown in Figure 6.

Concerning possible chemical approaches to explore the RONS scavenging-related metabolic fingerprint of antioxidants, biomimetic oxidative chemistry offers a readily available toolkit. Development and application of biomimetic or bio-inspired chemical reactions represent a rapidly emerging approach in today's chemistry. Such reactions use transition metals as catalysts either in free forms or in their complexes, for example as metalloporphyrins,<sup>151</sup> to perform various oxidative transformations similar to those observed in biological systems. A common feature of these types of reactions is that the oxidizing agent is an activated (ie reactive) oxygen or nitrogen species formed by electron transfer from the transition metal, aiming to mimic the way oxidase enzymes work.<sup>152,153</sup>

Accordingly, it is unsurprising that biomimetic approaches are extensively used in the total synthesis of natural products,<sup>154</sup> including various functionalization or cross-coupling reactions of phenolic/polyphenolic compounds.<sup>155-157</sup>

Nevertheless, more than providing a remarkable toolkit for solving synthetic chemical challenges, biomimetic oxidative chemistry also offers a platform to study the oxidative metabolism of drugs.<sup>158</sup> Such approaches require the best possible models of selected metabolizing oxidase enzymes. From a different perspective, however, biomimetic oxidative reactions can also be considered as reasonable chemical models for studying the potential impact of RONS on compounds including for example dietary antioxidants. Apparently, no related systematic studies have been performed so far, but sporadic reports can be found where one or more bioactivities of an

antioxidant were directly compared in the same pharmacological model to those of its oxidized metabolites obtained by biomimetic oxidative chemistry.

In the following sub-sections, chemically oxidized derivatives of compounds **1–9** will be presented from this perspective. For each compound, selected examples are discussed, in which the bioactivity of the parent antioxidant on specific pharmacological models could directly be compared to that of its chemically stable metabolite(s). An overview on these comparisons is provided in Table 1.

Since the field is extremely rich in reports on antioxidant natural products, it is almost certain that the below examples do not provide a complete coverage. Still, their chemical and pharmacological diversity might provide an overview suggesting that oxidative stress-related metabolites may represent an important piece of the antioxidant puzzle, which is frequently overlooked.

## 4.1 | Curcuminoids

In the case of curcumin (**1**; Figure 1) and its derivatives, oxidative changes have been extensively studied over the years as a likely explanation for the polypharmacology of these compounds.<sup>56,159</sup> Spontaneous aerobic oxidation of curcumin leads to the formation of a bicyclopentadione derivative (**1u**) as a major product<sup>160</sup>; for its chemical structure, see Figure 1B. A most recent, in-depth mechanistic study identified several intermediates (eg **1t** and **1v**) and by-products (**1s**, **1w**, **1x** and **1y**) of this metabolite, arising from a course of multiple chemical rearrangements initiated by the phenoxyl radical.<sup>161</sup> This radical is obviously among the primary products when curcumin participates in ROS scavenging. The broad chemical diversity of the subsequently forming intermediates and end-products raises many exciting questions concerning their bioactivities in relation to their parent compound **1**. Unfortunately, as of today, little is known about them. Topoisomerase II poisoning activity of curcumin<sup>162,163</sup> is clearly associated with its transformation: its activity could be observed only in oxidative conditions.<sup>164</sup> Moreover, the same oxidative activation applies for poisoning topoisomerase II $\alpha$  by demethoxycurcumin (**2**) and bisdemethoxycurcumin (**3**): the activity of both curcuminoids significantly increased when combined with K<sub>3</sub>Fe(CN)<sub>6</sub>, a biomimetic oxidative reagent.<sup>165</sup> Transformation route of both **2** and **3** was found to be related to that of curcumin, and **2** also yielded a bicyclopentadione derivative (**2r**) as major metabolite. Both **2** and **3** were, however, more stable to resist autoxidation, and **3** even required the addition of K<sub>3</sub>Fe(CN)<sub>6</sub> or H<sub>2</sub>O<sub>2</sub> and horseradish peroxidase (forming ROS) to transform to a bisdemetoxy-spiroepoxide (**3k**), and stop at that phase without converting to a bicyclopentadione.<sup>165</sup> In view of most recent studies, however, it seems that a great deal of the bioactivity of curcuminoids is connected rather to the intermediates of the autoxidation and not the stable bicyclopentadiones.<sup>166,167</sup> Sanidad et al found that, while curcumin (**1**) had potent antiproliferative and proapoptotic activity against colon cancer cells, and exerted anti-inflammatory activity through inhibition of the NF- $\kappa$ B signaling, both the mixture of the degradation products and **1r** were weaker or rather inactive in these bioassays.<sup>166</sup> However, by using an experimental setup that allowed *in situ* formation of the autoxidized products, Edwards et al found that NF- $\kappa$ B inhibition by curcumin depends on oxidative activation, and that this is due to the reactive electrophile intermediates covalently binding to signaling proteins, such as for example IKK $\beta$ . Very interestingly, and in line with the perspective discussed here, they could clearly connect this activity to the oxidative status of the cells, in other words, they demonstrated that oxidative stress modulates curcumin's bioactivity through the *in situ* formation of oxidized intermediates.<sup>167</sup>

Curcumin is also known to rapidly decompose in cell culture medium under aerobic, physiological conditions, that yield a set of cleaved products, such as trans-6-(4'-hydroxy-3'-methoxyphenyl)-2,4-dioxo-5-hexenal (**1z**) as major product, and ferulic acid (**1za**), ferulic aldehyde (**1zb**), feruloyl methane (**1zc**), vanillic acid (**1zd**), and vanillin (**1ze**) as minor metabolites.<sup>168,169</sup> These compounds have received attention in numerous studies with curcumin, leading to an intense discussion on their potential role in some previous controversial findings.<sup>159</sup> For example, they were suggested as potentially responsible for the xanthine oxidase (XO) inhibition by curcumin,<sup>170</sup> which was previously reported both with positive<sup>171</sup> and negative<sup>172</sup> results. Based on *in silico* predictions validated by experimental XO inhibitory activities of quercetin and luteolin, the side-chain cleaved metabolite **1z** was suggested as a strong inhibitor of the enzyme, while curcumin itself was too large to bind to the active center of XO.<sup>170</sup> In



contrast to this, the testing of curcumin and its cleaved metabolites **1z**, **1za**, **1zb**, **1zd**, and **1ze** against human recombinant cytochrome P (CYP) enzymes CYP1A2, CYP3A4, CYP2D6, CYP2C9 and CYP2B6 showed that while curcumin (**1**) can inhibit all of them, none of the metabolites were significantly active in this regard.<sup>169</sup>

In a recent debate initiated by comments on the results of Dhillon et al on the potential therapeutic use of large doses of orally administered curcumin in cancer patients,<sup>173</sup> the same degradation products were hypothesized to be responsible for its beneficial effect.<sup>174</sup> In their response, the authors disapproved this theory and presented evidence for the inactivity of **1za** and **1zc** for suppressing the activation of NF- $\kappa$ B, in contrast with the case of curcumin.<sup>175</sup> While the clinical relevance of the above-mentioned recent findings by Edwards et al<sup>167</sup> on this pathway is unclear, one could hypothesize a similar oxidative stress-related formation of reactive intermediates.

The theory suggesting high importance of the cleaved metabolites (**1z-1zc**) in the bioactivity of curcumin<sup>159</sup> has also been challenged; based on the fact that under biologically more relevant conditions they form in smaller amounts than the bicyclopentadione compound **1u**.<sup>176</sup> However, when encapsulated curcumin was administered to healthy human subjects through enriched bread, to at least partly protect it from phase I and II metabolism, vanillic and ferulic acids (**1zd** and **1za**, respectively) were detected as major metabolites.<sup>177</sup> While it is unknown how this would correlate to the amount of **1u**, which should possibly form *in vivo* depending on the oxidative status, these cleaved products may also play their role in curcumin's bioactivities, particularly concerning the XO and CYP enzyme inhibition.<sup>178</sup>

Altogether, curcumin (**1**) represents an excellent example for an antioxidant that can undergo many different types of oxidative transformations, apparently leading to an oxidative status-related change in its bioactivity profile. Considering that much of the related dispute appears to originate from different applied oxidative conditions, one must assume that the metabolite pattern arising in a biological system will greatly depend on the local microenvironment, for the types and levels of RONS to be scavenged.

## 4.2 | Resveratrol

In view of the possible biological role of oxidized metabolites of resveratrol (**4**; Figure 2), its bioactivity on lipoxygenase (LOX) enzyme demonstrates an interesting example. Resveratrol was reported as a potent competitive inhibitor ( $IC_{50} = 13 \mu M$ ) of the dioxygenase but not the hydroperoxidase activity of LOX. At the same time, LOX gradually oxidized resveratrol to an *in situ*, non-characterized derivative that was suggested to be similarly active on the dioxygenase activity of LOX as resveratrol itself.<sup>179</sup> More recently, resveratrol was involved in a study where 30 polyphenols were subjected to an  $Fe^{3+}$  catalyzed biomimetic aerobic oxidation and the resulting mixtures were screened for specific LOX inhibitory activity through the xynol orange (FOX) assay that measures the hydroperoxidase activity.<sup>180</sup> As expected, resveratrol itself was inactive at a concentration as high as  $100 \mu M$ , while its oxidized mixture exerted 98% inhibition at a concentration equivalent to  $50 \mu M$  of resveratrol, despite the rather low (33%) conversion. Isolation of the predominant metabolites led to the identification of two active dihydrobenzofurane dimers, compound **4m** and  $\delta$ -viniferin (**4n**); for the relevant structures, see Figure 2B. Further investigations revealed that the metabolite profile is highly dependent on the reaction conditions: by using excess  $CuCl_2$  in ethanol, compound **4m** was obtained at relatively higher yields, while oxidation with DPPH radical made compounds **4n** and **4o** (the latter inactive as LOX inhibitor) as preferred metabolites.<sup>180</sup> Besides the low conversion of resveratrol (**4**), it should be highlighted that more than 20 products were visible on the HPLC fingerprint of the active mixture. This mixture exerted a complete inhibition of LOX at a concentration equivalent to  $50 \mu M$  of resveratrol (**4**), implying that the activities reported for the individual metabolites **4n** and **4m** ( $IC_{50}$  values ca. 17 and  $62 \mu M$ , respectively) cannot explain the activity observed for the mixture that contained these compounds in a few percent amount only.<sup>180</sup> This suggests either the presence of further active metabolites exerting stronger LOX inhibitory activities than compounds **4m** and **4n**, or strong synergistic interactions between the minor compounds of the reaction mixture.

Considering the very low (free) resveratrol concentrations achievable *in vivo* (see Section 3.2), the biological relevance for the RONS-dependent formation of such dimers and/or oligomers might seem to be at least questionable. Certainly, it seems there can be only a very low chance that the intermediates formed upon RONS

scavenging would react with each other instead of for example GSH or other, endogenous compounds present in excess amounts. This is, however, not necessarily the case. NMR studies<sup>181</sup> and high-level *in silico* calculations<sup>182</sup> provided evidence for a very strong self-association of stilbenes stabilized by  $\pi$ - $\pi$  interactions in aqueous environment, which could explain the inconsistencies in the regio- and stereoselectivity observed in oxidative coupling reactions similar to the case above.<sup>182</sup> In addition to these implications, this also means that fully  $\pi$ -conjugated stilbenes (eg resveratrol) preferably stick together in the aqueous environment provided by a living organism. As such, there might be a reasonably high chance for the formation of dimer/oligomer metabolites of such antioxidants through cross-coupling upon RONS scavenging, and for related modulation of their bioactivity.


### 4.3 | Hydroxycinnamates

The oxidized metabolites of hydroxycinnamates may provide interesting and valuable insights into the antitumor activity of their parent compounds.

In a most recent, proof-of-concept study of our research group, methyl-*p*-coumarate (**5**; Figure 3) was studied for its potential to form bioactive metabolites upon free radical scavenging.<sup>183</sup> A hypervalent iodine reagent (PIFA) was used to obtain oxidized metabolite mixtures of compound **5**. PIFA can oxidize phenolic compounds through single-electron transfer (SET) whose intermediate can transform into the same phenoxyl radical upon deprotonation as that forming in a hydrogen-atom transfer (HAT) reaction. Therefore, it was expected that the use of this reagent would result in metabolites like those forming through free radical scavenging. Two metabolites (**5e** and **5f**; see Figure 3B) were identified with antitumor activities much stronger than that of compound **5**. Graviquinone (**5e**) had over 2 orders of magnitude stronger cytotoxicity on certain resistant cancer cell lines as compared to compound **5**. Ten  $\mu$ M of graviquinone (**5e**) induced DNA damage in NCI-H460 and NCI-H661 lung carcinoma cells while it exerted DNA protective activity in normal HaCaT cells as determined by the relative expression of Histone 2A.X. At the same concentration it modulated DNA damage response through the inhibition of Checkpoint kinase-1 (Chk1) phosphorylation and the induction of Checkpoint kinase-2 (Chk2) phosphorylation in MCF-7 cells. It was also demonstrated that graviquinone (**5e**) can be formed as the result of the Fenton reaction of compound **5**. *In silico* studies suggested that **5e** is a kinetic metabolite when methyl-*p*-coumarate (**5**) scavenges  $\cdot$ OH radicals. The fact that cytotoxic activity of methyl-*p*-coumarate (**5**) was also potentiated by  $\text{H}_2\text{O}_2$  is indirect evidence for the oxidative stress-related *in situ* formation of antitumor metabolites; for example compound **5e**.<sup>183</sup> It is also worth noting the structural similarity of compound **5e** to the above-mentioned *p*-quinol estrone derivative DHED (see Figure 6). This suggests that *p*-phenols in general can be transformed into their *p*-quinol analogs upon free radical scavenging. Moreover, such *p*-quinol derivatives, including DHED itself, might be worthy of further study for activity on checkpoint kinases Chk1/Chk2, two of the key enzymes involved in response to DNA damage. These kinases are important in cancer development and, possibly, treatment.<sup>184</sup>

Concerning other hydroxycinnamates, methyl caffeate (**6**) was reported as a weak-moderate antitumor agent against various cell lines with *in vitro* antiproliferative  $\text{IC}_{50}$  values at the medium-low micromolar range against MCF-7 breast cancer cell line (ca. 110  $\mu$ M).<sup>185</sup> Still, there are some studies showing much stronger antitumor effects for this compound, for example Balachandran et al observed cytotoxic activity of **6** against MCF-7 cells with an  $\text{IC}_{50}$  value as low as 0.62  $\mu$ M, and the involvement of several pro- and antiapoptotic genes in apoptotic cell death.<sup>186</sup>

$\text{Ag}_2\text{O}$  catalyzed biomimetic oxidation of a set of cinnamic acid methyl esters including compound **6** yield metabolites with highly potent antitumor activity, and compound **6m**, an oxidized dimer of **6**, exerts a particularly strong antiproliferative activity ( $\text{IC}_{50} < 10$  nM) against breast cancer cell lines MDA-MB-435, MDA-N and BT-549, and sub-micromolar activity against several other cell lines. Moreover, the 2*R*,3*R* enantiomer of compound **6l** (but not the inactive 2*S*,3*S*) was identified as an antitubulin agent as strong ( $\text{IC}_{50} = 6.0$   $\mu$ M) as combretastatin A-4,<sup>187</sup> a well-known natural inhibitor of tubulin polymerization. The same compound, the 2*R*,3*R* enantiomer of **6l**, was also found to exert potent antiangiogenic activity apparently without interfering with fibroblast growth factor-2 (FGF-2) or vascular endothelial growth factor (VEGF).<sup>188</sup> Moreover, in a recent, in-depth pharmacological study using *in vivo* and



**FIGURE 7** Contextualization of the chemical perspectives discussed in Section 4, in connection with the canonic view on antioxidant activity. (A) Role of antioxidants in interfering with the redox balance and redox-modulated biochemical pathways. The antioxidant may enter a redox cycle and exert its bioactivities through both its reduced and oxidized form. (B) Potential importance of minor, chemically stable oxidized metabolites that may form due to free radical scavenging. Depending on the antioxidant's chemical properties, the type of ROS/RNS scavenged, re-arrangements of emerging reactive intermediates and/or other secondary reactions, etc., a complex mixture of oxidized metabolites is expected to be present and interact with various cellular mechanisms involved in the regulation of many biochemical processes. This localized metabolite pattern may be characteristic to the microenvironment, implying a crosstalk between redox signaling and a co-existent “antioxidant-metabolite signaling”. Since individual oxidized metabolites tend to show higher chemical complexity than their parent antioxidant, they are also expectable to act in a more targeted way

3D cell culture models, Yin et al found that compound **6l** has a significant potential for further development of a clinically applicable antimetastatic agent.<sup>189</sup> Of significant pharmacological interest, compound **6l** exerts its activity mainly on the microenvironment of the tumor through inducing the IL-25 secretion of tumor-associated fibroblasts, and this effect could be achieved in mice at doses as low as 20 to 100  $\mu\text{g kg}^{-1}$  body weight.<sup>189</sup> The activity of compound **6** was not investigated, and it is hard to imagine that its activity would be like that of its oxidized metabolite **6l**. As for the antiangiogenic effect, compound **6** was reported to be inactive in zebrafish.<sup>190</sup>

In another related study, the racemic mixture of compound **7d**, obtained enzymatically from methyl ferulate (**7**), exerted a similarly strong *in vitro* antiangiogenic effect to that of **6l** (2*R*,3*R*). A significant decrease in the VEGF production was found in swine granulosa cells at 1  $\mu\text{M}$  concentration of this compound, and it also retained the antioxidant activity of its parent compound, methyl ferulate (**7**).<sup>191</sup> Contradictory results have been reported with ferulic acid and its effects on angiogenesis.<sup>192,193</sup> Ferulic acid was found to up-regulate cyclin D1 and VEGF in endothelial cells, leading to a proangiogenic effect,<sup>192</sup> while in the other study, antiangiogenic effect was found through downregulation of  $\bullet\text{NO}$ , which, depending on the cell type, can lead to VEGF downregulation.<sup>193</sup> This contradiction may be connected to the perspective presented here: namely, results that depend on the oxidative status of the studied system. The effect of ferulic acid would be tuned in either direction through possible variations in its metabolite profile likely including compounds similar to those obtained from methyl ferulate.

#### 4.4 | Secoisolariciresinol

The oxidation of secoisolariciresinol (**8**; Figure 4) was previously studied by employing 2,2'-azobis(isobutyronitrile) (AIBN), a radical oxidant initiator and ethyl linoleate dissolved in acetonitrile producing a lipophilic environment

that models biological membranes. Several products were obtained (for structures, see Figure 4B) including a quinone methide (**8f**), peroxy-*p*-quinol adducts with either the lipid or a thermally decomposed product of AIBN (**8e** and **8d**, respectively), and lariciresinol (**8g**), another natural lignan derivative.<sup>194</sup> Among these products, bioactivity data are only available for **8g**. This compound is also a potent antioxidant, although slightly weaker than its parent compound **8**.<sup>195</sup> Compounds **8g** and **8** were also isolated from the trunk of *Berberis koreana*, and both of them studied for their capacity to inhibit \*NO stress produced in LPS-activated BV-2 microglia cells. While lariciresinol (**8g**) was found somewhat more active than secoisolariciresinol (**8**), with IC<sub>50</sub> values of 51.8 and 87.6  $\mu$ M, respectively, this is a minor difference with little if any relevance in terms of a RONS-scavenging related bioactivity change.<sup>196</sup> However, much larger differences in the inhibitory activities of **8g** and **8** can be observed on differentiation and fat accumulation of adipocytes (IC<sub>50</sub> < 10 nM for **8g** vs. IC<sub>50</sub> > 100 nM for **8**).<sup>197</sup> These 1 to 2 orders of magnitude difference in potency means that even small amounts of **8g** formed from **8** may significantly modulate the overall bioactivity, perhaps in an oxidative stress-related manner. Nevertheless, **8g** formed through the oxidation of **8**, can still be metabolized to the same end-products as its parent compound. If **8g** reaches the large intestines, microbiota can transform it first to **8**, and subsequently to the bioactive metabolites enterodiol (**8c**) and enterolactone (**8d**) (Figure 4A and 4B).

## 4.5 | Luteolin

An obvious structural change of luteolin (**9**; Figure 5) upon RONS scavenging is the reversible formation of o-quinone from the catechol group - a change that is also catalyzed by many oxidase enzymes. This o-quinone can than either enter a redox cycle where it can contribute to the formation of certain types of ROS or react as a Michael acceptor with an appropriate nucleophile, such as glutathione (GSH). Due to their relatively high reactivity, such quinones are usually considered as toxic intermediates, while they can also have an effect on cellular signaling targets including the IKK complex, Keap1, and the JNK pathway through the Glutathione S-Transferase  $\pi$  1 (GST  $\pi$ 1). For more insight into this subject, see the recent perspective by Bolton and Dunlap.<sup>198</sup>

In connection with the above-mentioned reaction of luteolin quinone with GSH, an interesting study on its specific bioactivity was published by Balyan et al, that compared the GST  $\pi$  inhibitory activity of luteolin (**9**), its o-quinone (**9q**), and its glutathione conjugate (**9r**)<sup>199</sup> (for the structures, see Figure 5B). Luteolin itself exerted a weak or rather negligible GST inhibition, while both the quinone (**9q**) and the glutathione conjugate (**9r**) were identified as strong inhibitors. Luteolin (**9**) was a weak, reversible noncompetitive inhibitor. The quinone (**9q**) inhibited GST in an irreversible manner through a mixed mechanism. The glutathione conjugate (**9r**) acted as a strong, reversible competitive inhibitor of the GST enzyme.<sup>199</sup> Such a mechanism may play an interesting role in the antitumor effects of other catechol antioxidants as well, particularly in view of the typically elevated ROS levels in cancer cells<sup>200,201</sup> and the importance of various GST isozymes in detoxification of the cell and, consequently, in chemoresistance.<sup>202-204</sup>

## 5 | OUTLOOK

Dietary antioxidants interfere with biological processes through several mechanisms of action, including free radical scavenging, modulation of redox signaling pathways and transcription factors, and the formation of sometimes very complex metabolite fingerprints. All these mechanisms are clearly interconnected at multiple levels.

It is of particular interest that the formation of oxidized metabolites may occur through scavenging RONS, and, accordingly, this may directly depend on the level of oxidative stress. As herein discussed, a wide variety of pharmacologically active metabolites may form through the interaction of an antioxidant and a reactive oxygen or nitrogen species. Interestingly and somewhat unsurprisingly, such chemical transformations usually result in more complex chemical structures as compared to their parent compounds. In contrast, metabolic transformations by gut microbiota, for example, point towards simplicity, for example reduction, fragmentation – see a comparison between

Figures 1-5A and Figures 1-5B. Such increases in structural complexity imply a possible increase in target specificity. Since the oxidized metabolite pattern is dependent on the oxidative status, it must therefore strongly depend on the microenvironment, and so must be the related bioactivity pattern. In connection with the rapidly emerging “omics” concepts, this could possibly be translated as an existence of some kind of a “scavengome” for these antioxidants, defined as the chemical space represented by all their possible RONS scavenging-related metabolites influencing the overall bioactivity observed in complex biological systems.

From a biological point of view, specific bioactivity patterns of this “scavengome” would imply an oxidative stress-related, “direct” signaling role of locally emerging antioxidant metabolites. This may provide new answers and possible alternative explanations to much of the controversy still present in the field.

From a pharmacological and drug discovery perspective, the oxidative modulation of antioxidants' bioactivity suggests that such compounds may at least partly function as oxidative stress-activated pro-drugs. Considering that only marginal attention has been assigned to the RONS scavenging-related structural changes carried by antioxidants and to the related pharmacological consequences, these point towards an unexplored segment of chemical space that is apparently a treasury of bioactive molecules. Higher target specificity of these metabolites as compared to their parent antioxidants may also make them more attractive as lead compounds for drug discovery. A contextualization of this concept with the generally accepted mechanisms of function of antioxidants is presented in Figure 7.

From a practical point of view, it should be noted that any research efforts attempting to explore this “scavengome” would extensively rely on *in silico*, as well as modern analytical and preparative chromatographic techniques. A drug discovery initiative aiming to successfully explore the pharmacological potential of such metabolites should use state-of-the-art metabolomic techniques with oxidized mixtures obtained by various conditions. Moreover, considering the typically low expectable yield of individual oxidized products identified as hits on a given target, large-scale preparations are necessary for further development and these would also require precise, sophisticated methods. The rapidly developing field of oxidative continuous flow chemistry<sup>205</sup> may provide the required flexibility and timely throughput to overcome challenges for yield optimization.

Finally, it is important to underline that the oxidative stress-induced alteration of the bioactivity pattern of a given antioxidant is not necessarily beneficial for the organism affected by it. This may lead to undesirable side-effects, such as toxicity, or a loss of its *in vitro* promising activity to the *in vivo* and/or clinical phase studies (see some of the examples in Section 3). Even though few antioxidants have reached the bedside, most of the initially promising drug candidates yielded disappointing clinical outcomes.<sup>206</sup> Considering the environmental-related emergence of chronic diseases where oxidative stress plays a central role, there is greater need for effective and safe antioxidants with therapeutic relevance. Pharmacological aspects of the oxidative status-related metabolic fingerprint of an antioxidant may not only provide new candidates to develop on their own right, but also lead to understanding what chemical design is necessary to prevent certain unwanted modifications whenever that antioxidant meets its nemesis, a reactive oxygen or nitrogen species.

## ACKNOWLEDGEMENTS

Support from the National Research, Development and Innovation Office, Hungary (NKFIH; K119770), the Ministry of Human Capacities, Hungary grant 20391-3/2018/FEKUSTRAT, the János Bolyai fellowship of the Hungarian Academy of Sciences, the UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities, and the Kálmán Szász Prize are acknowledged. A special thanks to Dr. Ana Martins (Biological Research Centre, Szeged, Hungary) and Prof. Emer. Leonard Amaral (IHMT, Lisbon, Portugal) for the critical reading of the manuscript and related scientific discussion.

## ORCID

Attila Hunyadi  <http://orcid.org/0000-0003-0074-3472>

## REFERENCES

1. Egea J, Fabregat I, Frapart YM, et al. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). *Redox Biology*. 2017;13:94-162.
2. Sies H. 1 - *Oxidative Stress: Introductory Remarks*. *Oxidative Stress*. London: Academic Press; 1985:1-8. <https://www.elsevier.com/books/oxidative-stress/sies/978-0-12-642760-8>
3. Jones DP. Redefining Oxidative Stress. *Antioxidants & Redox Signaling*. 2006;8(9-10):1865-1879.
4. Rhee SG. Cell signaling. H<sub>2</sub>O<sub>2</sub>, a necessary evil for cell signaling. *Science (New York, N.Y.)*. 2006;312(5782):1882-1883.
5. Finkel T. Signal transduction by reactive oxygen species. *The Journal of cell biology*. 2011;194(1):7-15.
6. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. *Current biology: CB*. 2014;24(10):R453-R462.
7. Moldogazieva NT, Mokhosoev IM, Feldman NB, Lutsenko SV. ROS and RNS signalling: adaptive redox switches through oxidative/nitrosative protein modifications. *Free radical research*. 2018;52(5):507-543.
8. Niki E. Antioxidants: basic principles, emerging concepts, and problems. *Biomedical journal*. 2014;37(3):106-111.
9. Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. *Free radical biology & medicine*. 2014;66:24-35.
10. Sies H. Oxidative stress: a concept in redox biology and medicine. *Redox Biology*. 2015;4:180-183.
11. Nimse SB, Pal D. Free radicals, natural antioxidants, and their reaction mechanisms. *RSC Advances*. 2015;5(35):27986-28006.
12. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *The Journal of nutrition*. 2000;130(8S Suppl):2073s-2085s.
13. Teng H, Chen L. Polyphenols and Bioavailability: an update. *Critical Reviews in Food Science and Nutrition*. 2018. <https://doi.org/10.1080/10408398.2018.1437023>
14. Singh S, Singh RP. In Vitro Methods of Assay of Antioxidants: An Overview. *Food Reviews International*. 2008;24(4):392-415.
15. Bunaciu AA, Danet AF, Fleschin Ş, Aboul-Enein HY. Recent Applications for in Vitro Antioxidant Activity Assay. *Critical Reviews in Analytical Chemistry*. 2016;46(5):389-399.
16. Lü JM, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. *Journal of Cellular and Molecular Medicine*. 2010;14(4):840-860.
17. Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. *Chemico-biological interactions*. 2008;174(1):27-37.
18. Lorenz P, Roychowdhury S, Engelmann M, Wolf G, Horn TF. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. *Nitric oxide: biology and chemistry*. 2003;9(2):64-76.
19. Iuga C, Alvarez-Idaboy JR, Russo N. Antioxidant activity of trans-resveratrol toward hydroxyl and hydroperoxyl radicals: a quantum chemical and computational kinetics study. *The Journal of organic chemistry*. 2012;77(8):3868-3877.
20. Holthoff JH, Woodling KA, Doerge DR, Burns ST, Hinson JA, Mayeux PR. Resveratrol, a dietary polyphenolic phytoalexin, is a functional scavenger of peroxynitrite. *Biochemical pharmacology*. 2010;80(8):1260-1265.
21. Vlachogianni IC, Fragopoulou E, Kostakis IK, Antonopoulou S. In vitro assessment of antioxidant activity of tyrosol, resveratrol and their acetylated derivatives. *Food chemistry*. 2015;177:165-173.
22. Sova M. Antioxidant and antimicrobial activities of cinnamic acid derivatives. *Mini reviews in medicinal chemistry*. 2012;12(8):749-767.
23. Razzaghi-Asl N, Garrido J, Khazraei H, Borges F, Firuzi O. Antioxidant properties of hydroxycinnamic acids: a review of structure- activity relationships. *Current medicinal chemistry*. 2013;20(36):4436-4450.
24. Landete JM. Plant and mammalian lignans: A review of source, intake, metabolism, intestinal bacteria and health. *Food Research International*. 2012;46(1):410-424.
25. Pietta PG. Flavonoids as antioxidants. *Journal of natural products*. 2000;63(7):1035-1042.
26. Amic D, Davidovic-Amic D, Beslo D, Rastija V, Lucic B, Trinajstić N. SAR and QSAR of the antioxidant activity of flavonoids. *Current medicinal chemistry*. 2007;14(7):827-845.
27. Niki E. Role of vitamin E as a lipid-soluble peroxy radical scavenger: in vitro and in vivo evidence. *Free radical biology & medicine*. 2014;66:3-12.
28. Gough DR, Cotter TG. Hydrogen peroxide: a Jekyll and Hyde signalling molecule. *Cell death & disease*. 2011;2:e213.
29. Hayyan M, Hashim MA, AlNashef IM. Superoxide Ion: Generation and Chemical Implications. *Chemical Reviews*. 2016;116(5):3029-3085.
30. Bauer G. HOCl and the control of oncogenesis. *Journal of inorganic biochemistry*. 2018;179:10-23.
31. Bauer G. The Antitumor Effect of Singlet Oxygen. *Anticancer research*. 2016;36(11):5649-5663.
32. Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. *Nature chemical biology*. 2011;7(8):504-511.



33. Weidinger A, Kozlov AV. Biological Activities of Reactive Oxygen and Nitrogen Species: Oxidative Stress versus Signal Transduction. *Biomolecules*. 2015;5(2):472-484.
34. Sies H. Strategies of antioxidant defense. *European journal of biochemistry*. 1993;215(2):213-219.
35. Bartesaghi S, Radi R. Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration. *Redox biology*. 2017;14:618-625.
36. Bauer G. Increasing the endogenous NO level causes catalase inactivation and reactivation of intercellular apoptosis signaling specifically in tumor cells. *Redox Biol*. 2015;6:353-371.
37. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative Stress and Antioxidant Defense. *The World Allergy Organization journal*. 2012;5(1):9-19.
38. Shim SY, Kim HS. Oxidative stress and the antioxidant enzyme system in the developing brain. *Korean J Pediatr*. 2013;56(3):107-111.
39. Barrajon-Catalan E, Herranz-Lopez M, Joven J, et al. Molecular promiscuity of plant polyphenols in the management of age-related diseases: far beyond their antioxidant properties. *Advances in experimental medicine and biology*. 2014;824:141-159.
40. Huang S. Inhibition of PI3K/Akt/mTOR Signaling by Natural Products. *Anti-cancer agents in medicinal chemistry*. 2013;13(7):967-970.
41. Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. *Diabetes*. 2006;55(8):2180-2191.
42. Yong Y, Shin SY, Jung Y, et al. Flavonoids activating adenosine monophosphate-activated protein kinase. *Journal of the Korean Society for Applied Biological Chemistry*. 2015;58(1):13-19.
43. Lan F, Weikel KA, Cacicedo JM, Ido Y. Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application. *Nutrients*. 2017;9(7):751.
44. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. *Archives of biochemistry and biophysics*. 2010;501(1):79-90.
45. Jayasena T, Poljak A, Smythe G, Braidly N, Munch G, Sachdev P. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease. *Ageing research reviews*. 2013;12(4):867-883.
46. Rahnasto-Rilla M, Tyni J, Huovinen M, et al. Natural polyphenols as sirtuin 6 modulators. *Scientific Reports*. 2018;8(1):4163.
47. Karunaweera N, Raju R, Gyengesi E, Münch G. Plant polyphenols as inhibitors of NF- $\kappa$ B induced cytokine production —a potential anti-inflammatory treatment for Alzheimer's disease? *Frontiers in Molecular Neuroscience*. 2015;8:24.
48. Cherniack EP. The potential influence of plant polyphenols on the aging process. *Forschende Komplementarmedizin (2006)*. 2010;17(4):181-187.
49. van Duynhoven J, Vaughan EE, Jacobs DM, et al. Metabolic fate of polyphenols in the human superorganism. *Proceedings of the National Academy of Sciences*. 2011;108(Suppl 1):4531-4538.
50. Mar, #xed n L, et al. Bioavailability of Dietary Polyphenols and Gut Microbiota Metabolism: Antimicrobial Properties. *BioMed Research International*. 2015;2015:18.
51. Tomas-Barberan FA, Selma MV, Espin JC. Interactions of gut microbiota with dietary polyphenols and consequences to human health. *Current opinion in clinical nutrition and metabolic care*. 2016;19(6):471-476.
52. Stevens JF, Maier CS. The Chemistry of Gut Microbial Metabolism of Polyphenols. *Phytochemistry reviews: proceedings of the Phytochemical Society of Europe*. 2016;15(3):425-444.
53. Chen J, He ZM, Wang FL, et al. Curcumin and its promise as an anticancer drug: An analysis of its anticancer and antifungal effects in cancer and associated complications from invasive fungal infections. *European journal of pharmacology*. 2016;772:33-42.
54. Goozee KG, Shah TM, Sohrabi HR, et al. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease. *The British journal of nutrition*. 2016;115(3):449-465.
55. Gupta SC, Patchva S, Aggarwal BB. Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. *The AAPS Journal*. 2013;15(1):195-218.
56. Heger M, van Golen RF, Broekgaarden M, Michel MC. The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. *Pharmacological Reviews*. 2014;66(1):222-307.
57. Amalraj A, Pius A, Gopi S, Gopi S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives – A review. *Journal of Traditional and Complementary Medicine*. 2017;7(2):205-233.
58. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Molecular pharmaceutics*. 2007;4(6):807-818.
59. Gutierrez VO, Campos ML, Arcaro CA, et al. Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). *Evidence-based complementary and alternative medicine: eCAM*. 2015;2015:678218. 678218
60. Schneider C, Gordon ON, Edwards RL, Luis PB. Degradation of curcumin: From mechanism to biological implications. *Journal of agricultural and food chemistry*. 2015;63(35):7606-7614.

61. Metzler M, Pfeiffer E, Schulz Simone I, Dempe Julia S. Curcumin uptake and metabolism. *BioFactors (Oxford, England)*. 2012;39(1):14-20.
62. An C-Y, Sun Z-Z, Shen L, Ji H-F. Biotransformation of food spice curcumin by gut bacterium *Bacillus megaterium* DCMB-002 and its pharmacological implications. *Food & Nutrition Research*. 2017;61(1):1412814.
63. Tan S *Metabolism of curcuminoids by intestinal bacteria in vitro* 2015.
64. Ireson C, Orr S, Jones DJL, et al. Characterization of Metabolites of the Chemopreventive Agent Curcumin in Human and Rat Hepatocytes and in the Rat *in Vivo*, and Evaluation of Their Ability to Inhibit Phorbol Ester-induced Prostaglandin  $E_2$  Production. *Cancer Research*. 2001;61(3):1058-1064.
65. Hoehle SI, Pfeiffer E, Solyom AM, Metzler M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. *J Agric Food Chem*. 2006;54(3):756-764.
66. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2008;17(6):1411-1417.
67. Pan M-H, Huang T-M, Lin J-K. Biotransformation of Curcumin Through Reduction and Glucuronidation in Mice. *Drug Metabolism and Disposition*. 1999;27(4):486-494.
68. Li R, Wang Q, Fan J-R, et al. Metabolites Identification of Curcumin, Demethoxycurcumin and Bisdemethoxycurcumin in Rats After Oral Administration of Nanoparticle Formulations by Liquid Chromatography Coupled with Mass Spectrometry. *World Journal of Traditional Chinese Medicine*. 2016;2(4):29-37.
69. Jamil QUA, Jaerapong N, Zehl M, Jarukamjorn K, Jager W. Metabolism of Curcumin in Human Breast Cancer Cells: Impact of Sulfation on Cytotoxicity. *Planta medica*. 2017;83(12-13):1028-1034.
70. Wang J, Yu X, Zhang L, Wang L, Peng Z, Chen Y. The pharmacokinetics and tissue distribution of curcumin and its metabolites in mice. *Biomed Chromatogr*. 2018:e4267. <https://doi.org/10.1002/bmc.4267>
71. Zeng Y, Qiu F, Liu Y, Qu G, Yao X. Isolation and identification of phase 1 metabolites of demethoxycurcumin in rats. *Drug metabolism and disposition: the biological fate of chemicals*. 2007;35(9):1564-1573.
72. Pan MH, Lin-Shiau SY, Lin JK. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. *Biochem Pharmacol*. 2000;60(11):1665-1676.
73. Lee S-L, Huang W-J, Lin WW, Lee S-S, Chen C-H. Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. *Bioorganic & medicinal chemistry*. 2005;13(22):6175-6181.
74. Mohd Aluwi MFF, Rullah K, Yamin BM, et al. Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin  $E_2$  production in LPS-induced murine and human macrophages cell lines. *Bioorganic & medicinal chemistry letters*. 2016;26(10):2531-2538.
75. Huang Y, Cao S, Zhang Q, et al. Biological and pharmacological effects of hexahydrocurcumin, a metabolite of curcumin. *Archives of biochemistry and biophysics*. 2018;646:31-37.
76. Somporn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. *Biological & pharmaceutical bulletin*. 2007;30(1):74-78.
77. Chen WF, Deng SL, Zhou B, Yang L, Liu ZL. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. *Free radical biology & medicine*. 2006;40(3):526-535.
78. Morales NP, Sirijaroonwong S, Yamanont P, Phisalaphong C. Electron Paramagnetic Resonance Study of the Free Radical Scavenging Capacity of Curcumin and Its Demethoxy and Hydrogenated Derivatives. *Biological & pharmaceutical bulletin*. 2015;38(10):1478-1483.
79. Wicha P, Tocharus J, Janyou A, et al. *Hexahydrocurcumin protects against cerebral ischemia/reperfusion injury, attenuates inflammation, and improves antioxidant defenses in a rat stroke model*. 2017;12(12):e0189211.
80. Li W, Suwanwela NC, Patumraj S. Curcumin prevents reperfusion injury following ischemic stroke in rats via inhibition of NFkappaB, ICAM-1, MMP-9 and caspase-3 expression. *Molecular medicine reports*. 2017;16(4):4710-4720.
81. Kuo CN, Chen CH, Chen SN, et al. Anti-angiogenic effect of hexahydrocurcumin in rat corneal neovascularization. *International ophthalmology*. 2018;38(2):747-756.
82. Dybkowska E, Sadowska A, Swiderski F, Rakowska R, Wysocka K. The occurrence of resveratrol in foodstuffs and its potential for supporting cancer prevention and treatment. A review. *Roczniki Panstwowego Zakladu Higieny*. 2018;69(1):5-14.
83. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the *in vivo* evidence. *Nature reviews. Drug discovery*. 2006;5(6):493-506.
84. Pei W, Shengmin S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. *BioFactors (Oxford, England)*. 2018;44(1):16-25.
85. Boockock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. *Cancer epidemiology, biomarkers & prevention: a publication of*



- the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(6):1246-1252.
86. Gheldof N, Moco S, Chabert C, Teav T, Barron D, Hager J. Role of sulfotransferases in resveratrol metabolism in human adipocytes. *Molecular nutrition & food research*. 2017;61(10). <https://onlinelibrary.wiley.com/doi/epdf/10.1002/mnfr.201700020>
87. Herath W, Khan SI, Khan IA. Microbial metabolism. Part 14. Isolation and bioactivity evaluation of microbial metabolites of resveratrol. *Natural product research*. 2013;27(16):1437-1444.
88. Hoshino J, Park EJ, Kondratyuk TP, et al. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. *Journal of medicinal chemistry*. 2010;53(13):5033-5043.
89. Ruotolo R, Calani L, Fietta E, et al. Anti-estrogenic activity of a human resveratrol metabolite. *Nutrition, metabolism, and cardiovascular diseases: NMCD*. 2013;23(11):1086-1092.
90. Bresciani L, Calani L, Bocchi L, et al. Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. *Nutrition, metabolism, and cardiovascular diseases: NMCD*. 2014;24(4):408-415.
91. El-Seedi HR, Taher EA, Sheikh BY, et al. Chapter 8 - Hydroxycinnamic Acids: Natural Sources, Biosynthesis, Possible Biological Activities, and Roles in Islamic Medicine. In: Attaur R, ed. *Studies in Natural Products Chemistry*. Vol55. Elsevier; 2018:pp. 269-292.
92. Heleno SA, Martins A, Queiroz MJRP, Ferreira ICFR. Bioactivity of phenolic acids: Metabolites versus parent compounds: A review. *Food chemistry*. 2015;173:501-513.
93. Alam MA, Subhan N, Hossain H, et al. Hydroxycinnamic acid derivatives: a potential class of natural compounds for the management of lipid metabolism and obesity. *Nutrition & Metabolism*. 2016;13:27.
94. Kern SM, Bennett RN, Needs PW, Mellon FA, Kroon PA, Garcia-Conesa MT. Characterization of metabolites of hydroxycinnamates in the in vitro model of human small intestinal epithelium caco-2 cells. *J Agric Food Chem*. 2003;51(27):7884-7891.
95. Wong CC, Meinel W, Glatt H-R, et al. In vitro and in vivo conjugation of dietary hydroxycinnamic acids by UDP-glucuronosyltransferases and sulfotransferases in humans. *The Journal of Nutritional Biochemistry*. 2010;21(11):1060-1068.
96. Omar MH, Mullen W, Stalmach A, et al. Absorption, disposition, metabolism, and excretion of [3-(14)C]caffeic acid in rats. *J Agric Food Chem*. 2012;60(20):5205-5214.
97. Gonthier MP, Remesy C, Scalbert A, et al. Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota in vitro. *Biomedicine & Pharmacotherapy*. 2006;60(9):536-540.
98. Tomas-Barberan F, Garcia-Villalba R, Quartieri A, et al. In vitro transformation of chlorogenic acid by human gut microbiota. *Molecular nutrition & food research*. 2014;58(5):1122-1131.
99. Heleno SA, Ferreira ICFR, Calhella RC, Esteves AP, Martins A, Queiroz MJRP. Cytotoxicity of Coprinopsis atramentaria extract, organic acids and their synthesized methylated and glucuronate derivatives. *Food Research International*. 2014;55:170-175.
100. Adolphe JL, Whiting SJ, Juurink BH, Thorpe LU, Alcorn J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. *The British journal of nutrition*. 2010;103(7):929-938.
101. Imran M, Ahmad N, Anjum FM, et al. Potential protective properties of flax lignan secoisolariciresinol diglucoside. *Nutrition Journal*. 2015;14:71.
102. DeLuca JAA, Garcia-Villatoro EL, Allred CD. Flaxseed Bioactive Compounds and Colorectal Cancer Prevention. *Current Oncology Reports*. 2018;20(8):59.
103. Setchell KD, Brown NM, Zimmer-Nechemias L, Wolfe B, Jha P, Heubi JE. Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans. *Food & function*. 2014;5(3):491-501.
104. Touré A, Xueming X. Flaxseed Lignans: Source, Biosynthesis, Metabolism, Antioxidant Activity, Bio-Active Components, and Health Benefits. *Comprehensive Reviews in Food Science and Food Safety*. 2010;9(3):261-269.
105. Clavel T, Borrmann D, Braune A, Doré J, Blaut M. Occurrence and activity of human intestinal bacteria involved in the conversion of dietary lignans. *Anaerobe*. 2006;12(3):140-147.
106. Adlercreutz H, van der Wildt J, Kinzel J, et al. Lignan and isoflavonoid conjugates in human urine. *The Journal of steroid biochemistry and molecular biology*. 1995;52(1):97-103.
107. Jansen GH, Arts IC, Nielsen MW, Muller M, Hollman PC, Keijer J. Uptake and metabolism of enterolactone and enterodiol by human colon epithelial cells. *Archives of biochemistry and biophysics*. 2005;435(1):74-82.
108. Niemeyer HB, Honig D, Lange-Bohmer A, Jacobs E, Kulling SE, Metzler M. Oxidative metabolites of the mammalian lignans enterodiol and enterolactone in rat bile and urine. *J Agric Food Chem*. 2000;48(7):2910-2919.
109. Jacobs E, Metzler M. Oxidative metabolism of the mammalian lignans enterolactone and enterodiol by rat, pig, and human liver microsomes. *J Agric Food Chem*. 1999;47(3):1071-1077.

110. Wang L-Q. Mammalian phytoestrogens: enterodiol and enterolactone. *Journal of Chromatography B*. 2002;777(1):289-309.
111. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. *The Journal of steroid biochemistry and molecular biology*. 1993;44(2):147-153.
112. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. *The Journal of endocrinology*. 1995;147(2):295-302.
113. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17 $\beta$ -hydroxysteroid dehydrogenase in MCF-7 cells. *The Journal of steroid biochemistry and molecular biology*. 2005;94(5):461-467.
114. Liu H, Liu J, Wang S, et al. Enterolactone has stronger effects than enterodiol on ovarian cancer. *Journal of Ovarian Research*. 2017;10(1):49.
115. DeLuca JAA, Garcia-Villatoro EL, Allred CD. Flaxseed Bioactive Compounds and Colorectal Cancer Prevention. *Curr Oncol Rep*. 2018;20(8):59.
116. Chikara S, Lindsey K, Borowicz P, Christofidou-Solomidou M, Reindl KM. Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines. *BMC complementary and alternative medicine*. 2017;17(1):30.
117. Kwon Y. Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease. *Experimental Gerontology*. 2017;95:39-43.
118. Aziz N, Kim M-Y, Cho JY. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. *Journal of Ethnopharmacology*. 2018;225:342-358.
119. Dwight AJ. *Luteolin: Natural Occurrences, Therapeutic Applications and Health Effects*. Nova Science Publishers; 2015: 1-108. Incorporated.
120. P Li L, D Wu X, J Chen Z, et al. Hsp60 in caudal fin regeneration from *Paramisgurnus dabryanus*: molecular cloning and expression characterization. *Interspecies difference of luteolin and apigenin after oral administration of Chrysanthemum morifolium extract and prediction of human pharmacokinetics*. 2013;68:401-408.
121. Wu L, Liu J, Han W, et al. Time-Dependent Metabolism of Luteolin by Human UDP-Glucuronosyltransferases and Its Intestinal First-Pass Glucuronidation in Mice. *Journal of Agricultural and Food Chemistry*. 2015;63(39):8722-8733.
122. Kure A, Nakagawa K, Kondo M, et al. Metabolic Fate of Luteolin in Rats: Its Relationship to Anti-inflammatory Effect. *Journal of Agricultural and Food Chemistry*. 2016;64(21):4246-4254.
123. Wang L, Chen Q, Zhu L, et al. Metabolic Disposition of Luteolin Is Mediated by the Interplay of UDP-Glucuronosyltransferases and Catechol- O-Methyltransferases in Rats. *Drug Metabolism and Disposition*. 2017;45(3):306-315.
124. Deng C, Gao C, Tian X, et al. Pharmacokinetics, tissue distribution and excretion of luteolin and its major metabolites in rats: Metabolites predominate in blood, tissues and are mainly excreted via bile. *Journal of Functional Foods*. 2017;35:332-340.
125. Weiqun L, Wenting W, Hai Y, Dongliang W, Wenhua L. Influence of Intestinal Microbiota on the Catabolism of Flavonoids in Mice. *Journal of Food Science*. 2016;81(12):H3026-H3034.
126. Kure A, Nakagawa K, Kondo M, et al. Metabolic Fate of Luteolin in Rats: Its Relationship to Anti-inflammatory Effect. *J Agric Food Chem*. 2016;64(21):4246-4254.
127. Shimoi K, Saka N, Kaji K, Nozawa R, Kinai N. Metabolic fate of luteolin and its functional activity at focal site. *BioFactors (Oxford, England)*. 2000;12(1-4):181-186.
128. Shimoi K, Nakayama T. Glucuronidase deconjugation in inflammation. *Methods in enzymology*. 2005;400:263-272.
129. Molina C, Kissner R, Koppenol WH. Decomposition kinetics of peroxynitrite: influence of pH and buffer. *Dalton transactions (Cambridge, England: 2003)*. 2013;42(27):9898-9905.
130. Ramezani MS, Padmaja S, Koppenol WH. Nitration and Hydroxylation of Phenolic Compounds by Peroxynitrite. *Chemical Research in Toxicology*. 1996;9(1):232-240.
131. Arunachalam G, Samuel SM, Ding H, Trigg CR. Peroxynitrite Biology. In: Laher I, ed. *Systems Biology of Free Radicals and Antioxidants*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014;pp. 207-242.
132. Carcamo JM, Pedraza A, Borquez-Ojeda O, Zhang B, Sanchez R, Golde DW. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IkappaBalpha kinase beta. *Molecular and cellular biology*. 2004;24(15):6645-6652.
133. Morgan MJ, Liu Z-g. Crosstalk of reactive oxygen species and NF- $\kappa$ B signaling. *Cell research*. 2011;21(1):103-115.
134. Xia Y, Shen S, Verma IM. NF- $\kappa$ B, an active player in human cancers. *Cancer immunology research*. 2014;2(9):823-830.
135. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. *Molecular cancer*. 2013;12:86.
136. Heaney ML, Gardner JR, Karasavvas N, et al. Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs. *Cancer Research*. 2008;68(19):8031-8038.
137. van der Reest J, Gottlieb E. Anti-cancer effects of vitamin C revisited. *Cell research*. 2016;26(3):269-270.
138. Yun J, Mullarky E, Lu C, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. *Science (New York, N.Y.)*. 2015;350(6266):1391-1396.

139. Reczek CR, Chandel NS. CANCER. Revisiting vitamin C and cancer. *Science (New York, N.Y.)*. 2015;350(6266):1317-1318.
140. Morkel M, Riemer P, Bläker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. *Oncotarget*. 2015;6(25):20785-20800.
141. Furuya A, Uozaki M, Yamasaki H, Arakawa T, Arita M, Koyama AH. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. *International journal of molecular medicine*. 2008;22(4):541-545.
142. Gregory D, Hargrett D, Holmes D, Money E, Bachenheimer SL. Efficient replication by herpes simplex virus type 1 involves activation of the I $\kappa$ B kinase-I $\kappa$ B-p65 pathway. *Journal of virology*. 2004;78(24):13582-13590.
143. La Frazia S, Amici C, Santoro MG. Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor- $\kappa$ B. *Antiviral therapy*. 2006;11(8):995-1004.
144. Prokai L, Prokai-Tatrai K, Perjesi P, et al. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(20):11741-11746.
145. Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova AD, Simpkins JW. Quinol-based metabolic cycle for estrogens in rat liver microsomes. *Drug metabolism and disposition: the biological fate of chemicals*. 2003;31(6):701-704.
146. Rivera-Portalatin NM, Vera-Serrano JL, Prokai-Tatrai K, Prokai L. Comparison of estrogen-derived ortho-quinone and para-quinol concerning induction of oxidative stress. *The Journal of steroid biochemistry and molecular biology*. 2007;105(1-5):71-75.
147. Prokai L, Nguyen V, Szarka S, et al. The prodrug DHED selectively delivers 17 $\beta$ -estradiol to the brain for treating estrogen-responsive disorders. *Sci Transl Med*. 2015;7(297):297ra113.
148. Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA. A comparative evaluation of treatments with 17 $\beta$ -estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease. *Hormones and Behavior*. 2016;83:39-44.
149. Tschiffely AE, Schuh RA, Prokai-Tatrai K, Ottinger MA, Prokai L. An exploratory investigation of brain-selective estrogen treatment in males using a mouse model of Alzheimer's disease. *Horm Behav*. 2018;98:16-21.
150. Merchantaler I, Lane M, Sabnis G, et al. Treatment with an orally bioavailable prodrug of 17 $\beta$ -estradiol alleviates hot flashes without hormonal effects in the periphery. *Scientific Reports*. 2016;6:30721.
151. Barona-Castano JC, Carmona-Vargas CC, Brocksom TJ, de Oliveira KT. Porphyrins as Catalysts in Scalable Organic Reactions. *Molecules (Basel, Switzerland)*. 2016;21(3):310.
152. Que L, Jr., Tolman WB. Biologically inspired oxidation catalysis. *Nature*. 2008;455(7211):333-340.
153. Baglia RA, Zaragoza JPT, Goldberg DP. Biomimetic Reactivity of Oxygen-Derived Manganese and Iron Porphyrinoid Complexes. *Chemical Reviews*. 2017;117(21):13320-13352.
154. Li XW, Nay B. Transition metal-promoted biomimetic steps in total syntheses. *Natural product reports*. 2014;31(4):533-549.
155. Petit E, Lefevre D, Jacquet R, Pouysegur L, Deffieux D, Quideau S. Remarkable biomimetic chemoselective aerobic oxidation of flavano-ellagitannins found in oak-aged wine. *Angewandte Chemie (International ed. in English)*. 2013;52(44):11530-11533.
156. Esguerra KV, Fall Y, Lumb JP. A biomimetic catalytic aerobic functionalization of phenols. *Angewandte Chemie (International ed. in English)*. 2014;53(23):5877-5881.
157. Albertson AK, Lumb JP. A bio-inspired total synthesis of tetrahydrofuran lignans. *Angewandte Chemie (International ed. in English)*. 2015;54(7):2204-2208.
158. Földi T, Ignácz G, Decsi B, et al. Biomimetic Synthesis of Drug Metabolites in Batch and Continuous-Flow Reactors. *Chemistry - A European Journal*. 2018;24(37):9385-9392.
159. Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products? *Trends in molecular medicine*. 2012;18(3):138-144.
160. Griesser M, Pistis V, Suzuki T, Tejera N, Pratt DA, Schneider C. Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin. *J Biol Chem*. 2011;286(2):1114-1124.
161. Gordon ON, Luis PB, Sintim HO, Schneider C. Unraveling Curcumin Degradation: Autoxidation Proceeds Through Spiroepoxide And Vinyl ether Intermediates En Route To The Main Bicyclopentadione. *The Journal of Biological Chemistry*. 2015;290(8):4817-4828.
162. Martin-Cordero C, Lopez-Lazaro M, Galvez M, Ayuso MJ. Curcumin as a DNA topoisomerase II poison. *Journal of enzyme inhibition and medicinal chemistry*. 2003;18(6):505-509.
163. Lopez-Lazaro M, Willmore E, Jobson A, et al. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. *Journal of natural products*. 2007;70(12):1884-1888.
164. Ketron AC, Gordon ON, Schneider C, Osheroff N. Oxidative metabolites of curcumin poison human type II topoisomerases. *Biochemistry*. 2013;52(1):221-227.
165. Gordon ON, Luis PB, Ashley RE, Osheroff N, Schneider C. Oxidative Transformation of Demethoxy- and Bisdemethoxycurcumin: Products, Mechanism of Formation, and Poisoning of Human Topoisomerase II $\alpha$ . *Chem Res Toxicol*. 2015;28(5):989-996.

166. Sanidad KZ, Zhu J, Wang W, Du Z, Zhang G. Effects of stable degradation products of curcumin on cancer cell proliferation and inflammation. *Journal of agricultural and food chemistry*. 2016;64(48):9189-9195.
167. Edwards RL, Luis PB, Varuzza PV, et al. The anti-inflammatory activity of curcumin is mediated by its oxidative metabolites. *Journal of Biological Chemistry*. 2017;jbc. RA117:000123-021252.
168. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. *Journal of pharmaceutical and biomedical analysis*. 1997;15(12):1867-1876.
169. Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. *Toxicology*. 2007;235(1-2):83-91.
170. Shen L, Ji HF. Insights into the inhibition of xanthine oxidase by curcumin. *Bioorganic & medicinal chemistry letters*. 2009;19(21):5990-5993.
171. Lin JK, Shih CA. Inhibitory effect of curcumin on xanthine dehydrogenase/oxidase induced by phorbol-12-myristate-13-acetate in NIH3T3 cells. *Carcinogenesis*. 1994;15(8):1717-1721.
172. Pauff JM, Hille R. Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. *Journal of natural products*. 2009;72(4):725-731.
173. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2008;14(14):4491-4499.
174. Shen L, Ji HF. Contribution of degradation products to the anticancer activity of curcumin. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2009;15(22):7108. author reply 7108-7109
175. Dhillon N, Sung B, Kurzrock R, Aggarwal BB. Could Antitumor Activity of Curcumin in Patients Be due to Its Metabolites? A Response. *Clinical Cancer Research*. 2009;15(22):7108-7109.
176. Gordon ON, Schneider C. Vanillin and ferulic acid: not the major degradation products of curcumin. *Trends in molecular medicine*. 2012;18(7):361-363. author reply 363-364
177. Vitaglione P, Barone Lumaga R, Ferracane R, et al. Curcumin bioavailability from enriched bread: the effect of microencapsulated ingredients. *J Agric Food Chem*. 2012;60(13):3357-3366.
178. Shen L, Liu CC, An CY, Ji HF. How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies. *Sci Rep*. 2016;6:20872.
179. Pinto MC, Garcia-Barrado JA, Macias P. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. *J Agric Food Chem*. 1999;47(12):4842-4846.
180. Shingai Y, Fujimoto A, Nakamura M, Masuda T. Structure and function of the oxidation products of polyphenols and identification of potent lipoxygenase inhibitors from Fe-catalyzed oxidation of resveratrol. *J Agric Food Chem*. 2011;59(15):8180-8186.
181. Bonechi C, Martini S, Magnani A, Rossi C. Stacking interaction study of trans-resveratrol (trans-3,5,4'-trihydroxystilbene) in solution by Nuclear Magnetic Resonance and Fourier Transform Infrared Spectroscopy. *Magnetic resonance in chemistry: MRC*. 2008;46(7):625-629.
182. Velu SS, Di Meo F, Trouillas P, Sancho-Garcia JC, Weber JF. Regio- and stereocontrolled synthesis of oligostilbenoids: theoretical highlights at the supramolecular level. *Journal of natural products*. 2013;76(4):538-546.
183. Fási L, Di Meo F, Kuo C-Y, et al. Antioxidant-inspired drug discovery: antitumor metabolite is formed in situ from a hydroxycinnamic acid derivative upon free radical scavenging. *Journal of medicinal chemistry*. 2019;62:1657-1668.
184. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. *Nature Reviews Cancer*. 2012;12:587-598.
185. Etzenhouser B, Hansch C, Kapur S, Selassie CD. Mechanism of toxicity of esters of caffeic and dihydrocaffeic acids. *Bioorganic & medicinal chemistry*. 2001;9(1):199-209.
186. Balachandran C, Emi N, Arun Y, et al. In vitro anticancer activity of methyl caffeate isolated from *Solanum torvum* Swartz. fruit. *Chemico-biological interactions*. 2015;242:81-90.
187. Pieters L, Van Dyck S, Gao M, et al. Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerization. *Journal of medicinal chemistry*. 1999;42(26):5475-5481.
188. Apers S, Paper D, Burgermeister J, et al. Antiangiogenic activity of synthetic dihydrobenzofuran lignans. *Journal of natural products*. 2002;65(5):718-720.
189. Yin SY, Jian FY, Chen YH, et al. Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis. 2016;7:11311.
190. Li Y, Wang SF, Zhao YL, et al. Chemical constituents from *Clematis delavayi* var. *spinescens*. *Molecules (Basel, Switzerland)*. 2009;14(11):4433-4439.
191. Basini G, Spatafora C, Tringali C, Bussolati S, Grasselli F. Effects of a ferulate-derived dihydrobenzofuran neolignan on angiogenesis, steroidogenesis, and redox status in a swine cell model. *Journal of biomolecular screening*. 2014;19(9):1282-1289.
192. Wang J, Yuan Z, Zhao H, et al. Ferulic acid promotes endothelial cells proliferation through up-regulating cyclin D1 and VEGF. *J Ethnopharmacol*. 2011;137(2):992-997.

193. Hou Y, Yang J, Zhao G, Yuan Y. Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. *Journal of cellular biochemistry*. 2004;93(6):1203-1209.
194. Masuda T, Akiyama J, Fujimoto A, Yamauchi S, Maekawa T, Sone Y. Antioxidation reaction mechanism studies of phenolic lignans, identification of antioxidation products of secoisolariciresinol from lipid oxidation. *Food chemistry*. 2010;123(2):442-450.
195. Yamauchi S, Sugahara T, Matsugi J, et al. Effect of the Benzylic Structure of Lignan on Antioxidant Activity. *Bioscience, Biotechnology, and Biochemistry*. 2007;71(9):2283-2290.
196. Kim KH, Moon E, Choi SU, Kim SY, Lee KR. Biological evaluation of phenolic constituents from the trunk of *Berberis koreana*. *Bioorganic & medicinal chemistry letters*. 2011;21(8):2270-2273.
197. Biasiotto G, Penza M, Zanella I, et al. Oilseeds ameliorate metabolic parameters in male mice, while contained lignans inhibit 3T3-L1 adipocyte differentiation in vitro. *Eur J Nutr*. 2014;53(8):1685-1697.
198. Bolton JL, Dunlap T. Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects. *Chemical Research in Toxicology*. 2017;30(1):13-37.
199. Balyan R, Kudugunti SK, Hamad HA, Yousef MS, Moridani MY. Bioactivation of luteolin by tyrosinase selectively inhibits glutathione S-transferase. *Chemico-biological interactions*. 2015;240:208-218.
200. Liou GY, Storz P. Reactive oxygen species in cancer. *Free radical research*. 2010;44(5):479-496.
201. Nogueira V, Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2013;19(16):4309-4314.
202. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. *Oncogene*. 2002;22:7369-7375.
203. Singh S. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. *Cancer Chemotherapy and Pharmacology*. 2015;75(1):1-15.
204. Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. *Oncogenesis*. 2018;7(1):8.
205. Gemoets HP, Su Y, Shang M, Hessel V, Luque R, Noel T. Liquid phase oxidation chemistry in continuous-flow microreactors. *Chemical Society reviews*. 2016;45(1):83-117.
206. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. *Current medicinal chemistry*. 2011;18(25):3871-3888.

## AUTHOR'S BIOGRAPHIES

**Dr. Attila Hunyadi** obtained the PhD degree in 2007, in pharmacognosy from the University of Szeged, Szeged, Hungary. In 2008-2009, he was a postdoc at the Kaohsiung Medical University in Kaohsiung, Taiwan at the laboratory of Prof. Yang-Chang Wu, where he achieved breakthrough with the first one-step synthesis of an oxidized flavonoid derivative. He is now associate professor at the Institute of Pharmacognosy, University of Szeged. His main research interest lies in the isolation, characterization, and semi-synthetic modification of bioactive natural products. His research group is currently focusing on oxidative chemistry to prepare natural product metabolites, aiming at an antioxidant-inspired extension of chemical space to discover new lead compounds against drug resistance in cancer. He has been the recipient of several prestigious awards, including the Egon Stahl Award-in-Silver of the Society for Medicinal Plant and Natural Product Research (GA) in 2017, awarded for outstanding achievements in pharmacognosy and phytochemistry. He is the first Hungarian researcher recognized with this distinguished Award.

**How to cite this article:** Hunyadi A. The mechanism(s) of action of antioxidants: From scavenging reactive oxygen/nitrogen species to redox signaling and the generation of bioactive secondary metabolites. *Med Res Rev*. 2019;1-29. <https://doi.org/10.1002/med.21592>